US20130316383A1 - Methods of monitoring metabolic pathways - Google Patents

Methods of monitoring metabolic pathways Download PDF

Info

Publication number
US20130316383A1
US20130316383A1 US13/870,911 US201313870911A US2013316383A1 US 20130316383 A1 US20130316383 A1 US 20130316383A1 US 201313870911 A US201313870911 A US 201313870911A US 2013316383 A1 US2013316383 A1 US 2013316383A1
Authority
US
United States
Prior art keywords
extract
mevalonate
coa
enzyme
pyrophosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/870,911
Inventor
Sunil BAJAD
Michael Leavell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amyris Inc
Original Assignee
Amyris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US13/870,911 priority Critical patent/US20130316383A1/en
Application filed by Amyris Inc filed Critical Amyris Inc
Assigned to MAXWELL (MAURITIUS) PTE LTD reassignment MAXWELL (MAURITIUS) PTE LTD SECURITY AGREEMENT Assignors: Amyris, Inc.
Assigned to TOTAL ENERGIES NOUVELLES ACTIVITES USA reassignment TOTAL ENERGIES NOUVELLES ACTIVITES USA SECURITY AGREEMENT Assignors: Amyris, Inc.
Publication of US20130316383A1 publication Critical patent/US20130316383A1/en
Assigned to Amyris, Inc. reassignment Amyris, Inc. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: TOTAL ENERGIES NOUVELLES ACTIVITES USA, SAS (F/K/A TOTAL GAS & POWER USA, SAS)
Assigned to Amyris, Inc. reassignment Amyris, Inc. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: MAXWELL (MAURITIUS) PTE LTD
Assigned to AMYRIS BIOTECHNOLOGIES, INC. reassignment AMYRIS BIOTECHNOLOGIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAJAD, SUNIL, LEAVELL, MICHAEL
Assigned to Amyris, Inc. reassignment Amyris, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AMYRIS BIOTECHNOLOGIES, INC.
Assigned to HERCULES TECHNOLOGY GROWTH CAPITAL, INC. reassignment HERCULES TECHNOLOGY GROWTH CAPITAL, INC. SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Amyris, Inc.
Assigned to STEGODON CORPORATION reassignment STEGODON CORPORATION SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HERCULES CAPITAL INC.
Assigned to Amyris, Inc. reassignment Amyris, Inc. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: STEGODON CORPORATION
Abandoned legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/62Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P23/00Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double bonds, e.g. carotenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P5/00Preparation of hydrocarbons or halogenated hydrocarbons
    • C12P5/007Preparation of hydrocarbons or halogenated hydrocarbons containing one or more isoprene units, i.e. terpenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00Preparation of oxygen-containing organic compounds
    • C12P7/02Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic

Definitions

  • Isoprenoids are ubiquitous in nature. They comprise a diverse family of over 40,000 individual products, many of which are vital to living organisms. Isoprenoids serve to maintain cellular fluidity, electron transport, and other metabolic functions. A vast number of natural and synthetic isoprenoids are useful as pharmaceuticals, cosmetics, perfumes, pigments and colorants, fungicides, antiseptics, nutraceuticals, and fine chemical intermediates.
  • An isoprenoid product is typically composed of repeating five carbon isopentenyl diphosphate (IPP) units, although irregular isoprenoids and polyterpenes have been reported.
  • IPP isopentenyl diphosphate
  • DMAPP isomer dimethylallyl pyrophosphate
  • DXP mevalonate-independent or deoxyxylulose-5-phosphate
  • isoprenoids have been manufactured by extraction from natural sources such as plants, microbes, and animals.
  • the yield by way of extraction is usually very low due to a number of profound limitations.
  • most isoprenoids accumulate in nature in only small amounts.
  • the source organisms in general are not amenable to the large-scale cultivation that is necessary to produce commercially viable quantities of a desired isoprenoid.
  • the requirement of certain toxic solvents for isoprenoid extraction necessitates special handling and disposal procedures, and thus complicating the commercial production of isoprenoids.
  • the present invention provides compositions and methods related to the monitoring of mevalonate pathway metabolites.
  • the invention provides a method of quantitating a cofactor and a mevalonate pathway metabolite, comprising (a) providing an extract of a cell comprising said cofactor and said mevalonate pathway metabolite, wherein the extract exhibits a pH value of greater than about 7; and (b) quantitating said cofactor and said metabolite from said extract.
  • the invention provides a method of quantitating a cofactor and a mevalonate pathway metabolite, comprising (a) providing an extract of a cell comprising said cofactor and said mevalonate pathway metabolite, wherein the extract exhibits a pH value of greater than about 7; (b) dividing said extract of (a) into a plurality of aliquots, one of which being analyzed to quantitate individual metabolites of the mevalonate pathway except acetoacetyl-CoA, and to quantitate individual cofactors; and (c) adding an acid to at least one other aliquot, wherein said at least one other aliquot is analyzed to quantitate acetoacetyl CoA.
  • the cofactor may be selected from a first group consisting of NAD + , NADP + , NADH, NADPH, AMP, ADP, and ATP.
  • the metabolite may be selected from a second group consisting of CoA metabolite and non-CoA metabolite.
  • Non-CoA metabolites include farnesyl pyrophosphate, geranyl pyrophosphate, isopentenyl pyrophosphate, dimethylallyl pyrophosphate, mevalonate, mevalonate phosphate, and mevalonate pyrophosphate.
  • CoA metabolites include acetyl CoA, acetoacetyl-CoA, and 3-hydroxy-3-methylglutaryl-CoA.
  • the methods quantitate all cofactors and metabolites of the mevalonate pathway.
  • the step of quantitating is by mass spectrometry.
  • the step of quantitating may be by liquid chomatography in conjunction with mass spectrometry.
  • the invention also provides a method of quantitating all cofactors involved in the mevalonate pathway and all mevalonate pathway metabolites, comprising (a) providing an extract of a cell comprising said all cofactors and said all metabolites, wherein said extract comprises a buffer that stabilizes said cofactors and metabolites for at least about 8 hours; and (b) quantitating said all cofactors involved in the mevalonate pathway and said all metabolites from said extract.
  • the cofactors may be NAD + , NADP + , NADH, NADPH, AMP, ADP, and ATP, and said all metabolites may be Acetyl CoA, Acetoacetyl-CoA, 3-hydroxy-3-methylglutaryl-CoA, farnesyl pyrophosphate, geranyl pyrophosphate, isopentenyl pyrophosphate, dimethylallyl pyrophosphate, mevalonate, mevalonate phosphate, and mevalonate pyrophosphate.
  • the invention also provides an extract from a cell comprising a cofactor and a mevalonate pathway metabolite, wherein the extract exhibits a pH value greater than about 9 and comprises an alcohol, and wherein the cofactor and the metabolite are stable in said extract for at least about 8 hours.
  • the cofactor and the metabolite may also be stable in said extract for at least about 12 hours.
  • the alcohol is methanol.
  • a fermentation method comprising: (a) initiating a first fermentation reaction comprising a medium and a population of host cells under an initial fermentation condition suitable for producing an isoprenoid from mevalonate pathway; (b) simultaneously quantitating a cofactor and a mevalonate pathway metabolite from the first fermentation reaction, wherein said cofactor and said metabolite are produced by said host cells; (c) performing a second fermentation reaction wherein one or more parameters of the initial fermentation condition used during the first fermentation reaction is adjusted based on the amount of said cofactor and/or said metabolite quantitated in (b).
  • the one or more parameters of (c) support production of said isoprenoid at a level higher than that produced under said initial fermentation condition.
  • the cell is prokaryotic or bacterial.
  • the cell is eukaryotic.
  • the cell can be a yeast cell.
  • the isoprenoid may be, for example, an alcohol. In some embodiments, the isoprenoid is a hydrocarbon.
  • the present invention additionally describes a method of quantitating a plurality of types of mevalonate pathway metabolites, comprising: (a) providing an extract of a cell comprising said plurality of types of mevalonate pathway metabolites, wherein a first type of metabolite in said plurality is CoA mevalonate pathway metabolite selected from the group consisting of Acetyl-CoA, Acetoacetyl-CoA, and 3-hydroxy-3-methylglutaryl-CoA, and wherein a second type of metabolite in said plurality is non-CoA mevalonate pathway metabolite selected from the group consisting of farnesyl pyrophosphate, geranyl pyrophosphate, isopentenyl pyrophosphate, dimethylallyl pyrophosphate, mevalonate, mevalonate phosphate, and mevalonate pyrophosphate; and (b) quantitating said plurality of types of mevalonate pathway metabolites from said extract.
  • FIG. 1 is a schematic representation of the mevalonate (“MEV”) pathway for the production of isopentenyl pyrophosphate (“IPP”).
  • MEV mevalonate
  • IPP isopentenyl pyrophosphate
  • FIG. 2 is a schematic illustrating one embodiment of the inventive method comprising a quenching step; extraction step; and an optional washing step.
  • the samples are divided into two aliquots which are treated in different manners for mass spectrometry analysis using positive and negative ionization modes. This allows for the detection and quantification of MEV pathway metabolites and co-factors.
  • FIGS. 3A-3C show LC/MS/MS data collected from MEV pathway standards and demonstrates detectability and defined peak shape for MEV pathway metabolites and co-factors.
  • FIGS. 4A-4C shows effects of using a basic, neutral, or acidic extraction buffer on recovery of intracellular metabolites and co-factors.
  • FIG. 5 shows stability of metabolites and co-factors in cell-extracts after extraction. As it can be seen, acetoacetyl CoA degrades with time.
  • FIG. 6 shows the stability of acetoacetyl CoA with and without extract acidification (e.g. such as by the addition of 0.1% formic acid (FA)).
  • FA formic acid
  • FIG. 7 shows the effect of each processing step to the temperature (in Celsius) of the sample: Processing step I—quenching solvent on dry ice; II—solvent and broth at quenching; III—after 1 minute on dry ice; IV—after centrifugation at ⁇ 10° C.; V—after extraction solvent was added; VI, sonication; VII—after 10 minutes on wet ice; VIII—after 5 minutes on wet ice; IX—after centrifugation at ⁇ 4° C.
  • FIGS. 8A-8D illustrate the effects of the addition of water or glycerol or both to 100% methanol on the detection of representative intracellular metabolites.
  • the best quenching solvent in this experiment was determined to be 65% methanol, 30% water and 5% glycerol.
  • FIG. 9 illustrate the effects of various amounts of glycerol to the detection of FAD and NAD. As it can be seen, better detection was observed with less than 40% glycerol (such as 20%, 10%, and 5%) than with 40% glycerol.
  • FIGS. 10A-10B compare the analysis of ATP, NADH and NADPH in negative and positive modes.
  • the terms “metabolic pathway” is used herein to refer to a catabolic pathway or an anabolic pathway.
  • Anabolic pathways involve constructing a larger molecule from smaller molecules, a process requiring energy. Catabolic pathways involve breaking down of larger molecules, often releasing energy.
  • the term “mevalonate pathway” or “MEV pathway” is used herein to refer to the biosynthetic pathway that converts acetyl-CoA to IPP.
  • the MEV pathway is illustrated schematically in FIG. 1 .
  • mevalonate pathway metabolite includes precursors, intermediates and products of the mevalonate pathway.
  • CoA mevalonate pathway metabolites include Acetyl-CoA, Acetoacetyl-CoA and 3-hydroxy-3-methylglutaryl-CoA.
  • Non-CoA mevalonate pathway metabolites include other mevalonate pathway metabolites such as farnesyl pyrophosphate, geranyl pyrophosphate, isopentenyl pyrophosphate, dimethylallyl pyrophosphate, mevalonate, mevalonate phosphate, and mevalonate pyrophosphate.
  • cofactor refers to a nonprotein component which participates in an enzymatic reaction. Cofactors which are involved in the mevalonate pathway include, but are not limited to, adenosine monophosphate (AMP), adenosine diphosphate (ADP), adenosine triphosphate (ATP), nicotinamide adenine dinucleotide (NAD + , NADH) and nicotinamide adenine dinucleotide phosphate (NADP + , NADPH).
  • AMP adenosine monophosphate
  • ADP adenosine diphosphate
  • ATP adenosine triphosphate
  • NAD + nicotinamide adenine dinucleotide
  • NADP + nicotinamide adenine dinucleotide phosphate
  • Acetyl-CoA is both a cofactor and a CoA mevalonate pathway metabolite.
  • extract refers to a cell product obtained from a cell or collection of cells, for example a prokaryotic or eukaryotic cell culture.
  • An extract may comprise intracellular and extracellular components of a cell, as well as parts of the fluid or solid medium in which the cell has been grown, as well as any buffers or additional reagents that may be used in the extraction procedure. Extracts are commonly liquids, solids, or may be liquids comprising solid fragments such as cellular fractions or precipitates.
  • cell refers to any archae, eukaryotic or prokaryotic organisms comprising at least part of the mevalonate pathway. Such organisms may be naturally occurring or may be genetically modified by insertion of a vector expressing a desired nucleic acid or polypeptide sequence or a vector comprising a sequence to alter the expression of a polypeptide endogenous to the host cell.
  • aliquot refers to a fraction of an extract isolated at any step during an extraction procedure.
  • RSD relative standard deviation
  • pH value expresses the degree of acidity or basicity of a solution.
  • acidifying refers to a step in which an acidic solution is added to another solution to lower the initial pH value, resulting in a solution which may be acidic, neutral or even basic, depending on the amount of acidic solution added.
  • basic refers to a step in which a basic solution is added to another solution to raise the initial pH value, resulting in a solution which may be basic, neutral or even acidic, depending on the amount of basic solution added.
  • pyrophosphate is used interchangeably herein with “diphosphate”.
  • endogenous refers to a substance or process that occurs naturally, e.g., in a non-recombinant host cell.
  • nucleic acid and “polynucleotide” are used interchangeably. They refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxynucleotides. Thus, this term includes, but is not limited to, single-, double-, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or a polymer comprising purine and pyrimidine bases or other natural, chemically, or biochemically modified, non-natural, or derivatized nucleotide bases.
  • protein refers to a polymeric form of amino acids of any length, which can include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified peptide backbones.
  • nucleic acid refers to a nucleic acid, enzyme, cell, or organism that is found in nature.
  • a polypeptide or polynucleotide sequence that is present in an organism that can be isolated from a source in nature and that has not been intentionally modified by a human in the laboratory is naturally occurring.
  • isoprenoid refers to compounds that are capable of being derived from IPP.
  • this invention is not limited to particular compounds, cofactors, intermediates, metabolites, enzymes, microorganisms, or processes, and as such may vary in accordance with the understanding of those of ordinary skill in the arts to which this invention pertains in view of the teaching herein. Terminology used herein is for purposes of describing particular embodiments only and is not intended to be limiting.
  • Any suitable cell may be used in the practice of the present invention.
  • suitable cells include any archae, prokaryotic, or eukaryotic cell that comprises the entire or part of the mevalonate pathway.
  • archae cell include, but are not limited to those belonging to the genera: Aeropyrum, Archaeglobus, Halobacterium, Methanococcus, Methanobacterium, Pyrococcus, Sulfolobus , and Thermoplasma .
  • archae strains include but are not limited to: Aeropyrum pernix, Archaeoglobus fulgidus, Methanococcus jannaschii, Methanobacterium thermoautotrophicum, Pyrococcus abyssi, Pyrococcus horikoshii, Thermoplasma acidophilum, Thermoplasma volcanium.
  • Examples of a procaryotic cell include, but are not limited to those belonging to the genera: Agrobacterium, Alicyclobacillus, Anabaena, Anacystis, Arthrobacter, Azobacter, Bacillus, Brevibacterium, Chromatium, Clostridium, Corynebacterium, Enterobacter, Erwinia, Escherichia, Lactobacillus, Lactococcus, Mesorhizobium, Methylobacterium, Microbacterium, Phormidium, Pseudomonas, Rhodobacter, Rhodopseudomonas, Rhodospirillum, Rhodococcus, Salmonella, Scenedesmun, Serratia, Shigella, Staphlococcus, Strepromyces, Synnecoccus , and Zymomonas.
  • prokaryotic bacterial strains include but are not limited to: Bacillus subtilis, Bacillus amyloliquefacines, Brevibacterium ammoniagenes, Brevibacterium immariophilum, Clostridium beigerinckii, Enterobacter sakazakii, Escherichia coli, Lactococcus lactis, Mesorhizobium loti, Pseudomonas aeruginosa, Pseudomonas mevalonii, Pseudomonas pudica, Rhodobacter capsulatus, Rhodobacter sphaeroides, Rhodospirillum rubrum, Salmonella enterica, Salmonella typhi, Salmonella typhimurium, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Staphylococcus aureus , and the like.
  • non-pathogenic strain In general, if a bacterial host cell is used, a non-pathogenic strain is generally preferred.
  • non-pathogenic strains include but are not limited to: Bacillus subtilis, Escherichia coli, Lactibacillus acidophilus, Lactobacillus helveticus, Pseudomonas aeruginosa, Pseudomonas mevalonii, Pseudomonas pudita, Rhodobacter sphaeroides, Rodobacter capsulatus, Rhodospirillum rubrum , and the like.
  • Examples of eukaryotic cells include but are not limited to fungal cells.
  • Examples of fungal cell include, but are not limited to those belonging to the genera: Aspergillus, Candida, Chrysosporium, Cryotococcus, Fusarium, Kluyveromyces, Neotyphodium, Neurospora, Penicillium, Pichia, Saccharomyces, Trichoderma and Xanthophyllomyces (formerly Phaffia ).
  • Illustrative examples of eukaryotic strains include but are not limited to: Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Candida albicans, Chrysosporium lucknowense, Fusarium graminearum, Fusarium venenatum, Kluyveromyces lactis, Neurospora crassa, Pichia angusta, Pichia finlandica, Pichia kodamae, Pichia membranaefaciens, Pichia methanolica, Pichia opuntiae, Pichia pastoris, Pichia pijperi, Pichia quercuum, Pichia salictaria, Pichia thermotolerans, Pichia trehalophila, Pichia stipitis, Streptomyces ambofaciens, Streptomyces aureofaciens, Streptomyces aureus, Saccaromy
  • non-pathogenic strain In general, if a eukaryotic cell is used, a non-pathogenic strain is preferred.
  • non-pathogenic strains include but are not limited to: Fusarium graminearum, Fusarium venenatum, Pichia pastoris, Saccaromyces boulardi , and Saccaromyces cerevisiae.
  • strains have been designated by the Food and Drug Administration as GRAS or Generally Regarded As Safe. These strains include: Bacillus subtilis, Lactibacillus acidophilus, Lactobacillus helveticus , and Saccharomyces cerevisiae.
  • the cell is a genetically modified host microorganism in which nucleic acid molecules have been inserted, deleted or modified (i.e., mutated; e.g., by insertion, deletion, substitution, and/or inversion of nucleotides), to either produce the desired isoprenoid compound or isoprenoid derivative, or effect an increased yield of the desired isoprenoid compound or isoprenoid derivative.
  • the host cell is capable of being grown in liquid growth medium.
  • a “control cell” is an alternative subject or sample used in an experiment for comparison purpose, and is typically a parental cell that does not contain the modification(s) made to a corresponding host cell.
  • the cells of the present invention typically comprise or utilize the MEV pathway, and possibly the DXP pathway to synthesize IPP and its isomer, DMAPP.
  • MEV MEV isoprenoid pathway exclusively to convert acetyl-CoA to IPP, which is subsequently isomerized to DMAPP.
  • Prokaryotes use the mevalonate-independent or DXP pathway to produce IPP and DMAPP separately through a branch point.
  • plants use both the MEV and DXP pathways for IPP synthesis.
  • FIG. 1 A schematic representation of the MEV pathway is described in FIG. 1 .
  • two molecules of acetyl-coenzyme A are enzymatically combined to form acetoacetyl-CoA.
  • An enzyme known to catalyze this step is, for example, acetyl-CoA thiolase (also known as acetyl-CoA acetyltransferase).
  • acetoacetyl-CoA is enzymatically condensed with another molecule of acetyl-CoA to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA).
  • An enzyme known to catalyze this step is, for example, HMG-CoA synthase.
  • HMG-CoA is enzymatically converted to mevalonate.
  • An enzyme known to catalyze this step is, for example, HMG-CoA reductase.
  • mevalonate is enzymatically phosphorylated to form mevalonate 5-phosphate.
  • An enzyme known to catalyze this step is, for example, mevalonate kinase.
  • a second phosphate group is enzymatically added to mevalonate 5-phosphate to form mevalonate 5-pyrophosphate.
  • An enzyme known to catalyze this step is, for example, phosphomevalonate kinase.
  • mevalonate 5-pyrophosphate is enzymatically converted into IPP.
  • An enzyme known to catalyze this step is, for example, mevalonate pyrophosphate decarboxylase.
  • a seventh step is required.
  • An enzyme known to catalyze this step is, for example, IPP isomerase. If the conversion to DMAPP is required, an increased expression of IPP isomerase ensures that the conversion of IPP into DMAPP does not represent a rate-limiting step in the overall pathway.
  • the host cell produces IPP via the MEV pathway, either exclusively or in combination with the DXP pathway.
  • a host's DXP pathway is functionally disabled so that the host cell produces IPP exclusively through a heterologously introduced MEV pathway.
  • the DXP pathway can be functionally disabled by disabling gene expression or inactivating the function of one or more of the DXP pathway enzymes.
  • the metabolites DMAPP and IPP can undergo further reactions to produce additional metabolites.
  • the enzyme farnesyl pyrophosphate synthase can catalyze sequential condensation reactions of dimethylallyl pyrophosphate with 2 units of 3-isopentenyl pyrophosphate to form farnesyl pyrophosphate (FPP).
  • FPP farnesyl pyrophosphate
  • DMAPP may react with IPP to form geranyl pyrophosphate (GPP).
  • GPP geranyl pyrophosphate
  • one molecule of GPP may react with IPP to form one molecule of FPP.
  • additional metabolites which may be produced by the mevalonate pathway.
  • the metabolites and the cofactors involved in the mevalonate pathway have a wide spectrum of physiochemical properties which makes quantification of these components problematic.
  • these compounds can be phosphorylated (mono, di, or tri) or non-phosphorylated. They also span the range from hydrophobic to hydrophilic.
  • Certain metabolites such as isopentenyl pyrophosphate, dimethylallyl phyrophosphate, farnesyl pyrophosphate, NADPH and NADH are unstable in acidic solvents whereas ATP and CoAs are more stable in acidic solvents. Because of the complications involved, simultaneous analyses of these metabolites have not been previously attempted. Surprisingly, extraction of the cell metabolites in an extraction solvent with a pH greater than about 7, allows for the detection of all cofactors and metabolites.
  • a method comprising:
  • the cell extract exhibits a pH value greater than or equal to about 8. In other embodiments, the cell extract exhibits a pH value greater than or equal to about 9. In still other embodiments, the cell extract exhibits a pH value greater than or equal to about 9.4.
  • the cell extract exhibits a pH value of between 8 and 13. In some embodiments, the cell extract exhibits a pH value of between 8 and 11. In some embodiments, the cell extract exhibits a pH value of between 8 and 10. In some embodiments, the cell extract exhibits a pH value of between 9 and 13. In some embodiments, the cell extract exhibits a pH value of between 9 and 12. In some embodiments, the cell extract exhibits a pH value of between 9 and 11. In some embodiments, the cell extract exhibits a pH value of between 9 and 10.
  • the pH of the cell extract is due to the addition of an extraction solvent having a pH value greater than about 7. In certain embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value greater than or equal to about 8. In other embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value greater than or equal to about 9. In still other embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value greater than or equal to about 9.4.
  • the pH of the cell extract is due to the addition of an extraction solvent having a pH value of between 7 and 13. In some embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value of between 7 and 10. In some embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value of between 7 and 9. In some embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value of between 8 and 13. In some embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value of between 8 and 11. In some embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value of between 8 and 10.
  • the pH of the cell extract is due to the addition of an extraction solvent having a pH value of between 9 and 13. In some embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value of between 9 and 11. In some embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value of between 9 and 10.
  • the extraction solvent comprises an alcohol and a basic buffer.
  • the alcohol is a C 1 -C 5 alcohol.
  • the alcohol is methanol or ethanol.
  • Any suitable basic buffer can be used.
  • Such a buffer may comprise cationic and anionic species such that the buffering capacity is sufficient around the desired pH.
  • suitable cationic species include an ammonium salt such as ammonium chloride, ammonium acetate, and the like.
  • the ratio of alcohol to basic buffer can be about 1.
  • An illustrative example is a 1:1 solution of alcohol such as methanol to basic buffer such as ammonium acetate.
  • the ration of alcohol to basic buffer is greater than 2.
  • An illustrative example is a solution comprising 70% methanol and 30% basic buffer such as ammonium acetate.
  • the cofactor is NADH and/or NADPH. In another embodiment, the cofactor is ATP, ADP, AMP or any combination thereof.
  • the mevalonate pathway metabolite is a CoA mevalonate pathway metabolite such as Acetyl-CoA, Acetoacetyl-CoA or 3-hydroxy-3-methylglutaryl-CoA. In yet another embodiment, the mevalonate pathway metabolite is Acetoacetyl-CoA or 3-hydroxy-3-methylglutaryl-CoA. In another embodiment, the mevalonate pathway metabolite is IPP or DMAPP.
  • the mevalonate pathway metabolite is mevalonate, mevalonate phosphate or mevalonate pyrophosphate.
  • all cofactors from the group consisting of NAD+, NADP+, NADH, NADPH, AMP, ADP, and ATP are quantitated.
  • all metabolites from the group consisting of Acetyl-CoA, Acetoacetyl-CoA, 3-hydroxy-3-methylglutaryl-CoA, farnesyl pyrophosphate, geranyl pyrophosphate, isopentenyl pyrophosphate, dimethylallyl pyrophosphate, mevalonate, mevalonate phosphate, and mevalonate pyrophosphate are quantitated.
  • the invention provides a method of quantitating a plurality of types of mevalonate pathway metabolites, including a first and second type of metabolites.
  • the first type of metabolite may be a CoA mevalonate pathway metabolite, including Acetyl-CoA, Acetoacetyl-CoA, and 3-hydroxy-3-methylglutaryl-CoA
  • the second type of metabolite may be a non-CoA mevalonate pathway metabolite, including farnesyl pyrophosphate, geranyl pyrophosphate, isopentenyl pyrophosphate, dimethylallyl pyrophosphate, mevalonate, mevalonate phosphate and mevalonate pyrophosphate.
  • the quenching solvent is a liquid at about ⁇ 80° C. In other embodiments, the quenching solvent comprises methanol. In still other embodiments, the quenching solvent comprises methanol and glycerol. In certain other embodiments, the quenching solvent comprises methanol and glycerol and remains a liquid at ⁇ 80° C.
  • the temperature of the first mixture is less than about ⁇ 23° C. In certain other embodiments, the temperature of the first mixture is equal to or less than about ⁇ 30° C. In still other embodiments, the temperature of the first mixture is less than about ⁇ 30° C.
  • the first mixture is centrifuged to separate the cells from the quenching solvent.
  • the first mixture comprises the resulting cell pellet.
  • the second mixture exhibits a pH value greater than or equal to about 8. In other embodiments, the second mixture exhibits a pH value greater than or equal to about 9. In still other embodiments, the second mixture exhibits a pH value greater than or equal to about 9.4.
  • the second mixture exhibits a pH value between 8 and 13. In certain embodiments, the second mixture exhibits a pH value between 8 and 11. In certain embodiments, the second mixture exhibits a pH value between 8 and 10. In certain embodiments, the second mixture exhibits a pH value between 9 and 13. In certain embodiments, the second mixture exhibits a pH value between 9 and 11. In certain embodiments, the second mixture exhibits a pH value between 9 and 10.
  • the pH of the second mixture is due to the addition of an extraction solvent having a pH value greater than about 7. In certain embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value greater than or equal to about 8. In other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value greater than or equal to about 9. In still other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value greater than or equal to about 9.4.
  • the pH of the second mixture is due to the addition of an extraction solvent having a pH value between about 7 and 13. In certain other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value between about 7 and 11. In certain other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value between about 7 and 9. In certain other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value between about 8 and 13. In certain other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value between about 8 and 11. In certain other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value between about 8 and 10.
  • the pH of the second mixture is due to the addition of an extraction solvent having a pH value between about 9 and 13. In certain other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value between about 9 and 11. In certain other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value between about 9 and 10.
  • Additional processing steps to improve quantification include breaking open the cells to allow the cofactor and metabolite into the solution of the second mixture. Any method known in the art can be used to break open the cells such as vortexing and sonication or a combination of both. In some embodiments, glass beads can be used to facilitate by mechanical means to break open the cells. Other processing steps can include centrifugation to remove unwanted cell debris from the supernatant.
  • the second mixture can be divided into a plurality of aliquots so that each aliquot can be subsequently processed different to stabilize certain metabolites.
  • stable or “stabilized” refers to at least 50% of the initial concentration of a cofactor or metabolite remaining in an extract in a given time period.
  • Cofactors and metabolites described in the invention are be stable for at least 1, 2, 3, 4, 5, 7, 8, 16, or 24 hours.
  • the cofactors involved in the mevalonate pathway and mevalonate pathway metabolites are stable for at least about 8 hours. In other embodiments, the cofactors and the metabolites are stable for at least about 12 hours.
  • At least one of these aliquots is acidified to stabilize CoAs and ATP. In other embodiments, at least one of these aliquots is acidified to stabilize CoAs. In still other embodiments, at least one of these aliquots is acidified to stabilize ATP. In yet other embodiments, at least one of these aliquots is acidified to stabilize acetoacetyl-CoA. Any suitable acid which can acidify an otherwise basic solution can be added to at least one of the aliquots of the second mixture. Prior to quantification, the plurality of aliquots can then be diluted as necessary with a suitable solvent such as methanol to optimize the concentrations of the cofactors and metabolites in the sample for analyses.
  • a suitable solvent such as methanol
  • the at least one cofactor and metabolite includes a CoA or ATP. In other embodiments, the at least one cofactor and metabolite includes a CoA. In still other embodiments, the at least one cofactor and metabolite includes acetoacetyl CoA.
  • Quantification may be by any method known in the art. In some embodiments, liquid chromatography is used.
  • elution buffers columns and parameters are known in the art, and may be used to perform the method of the invention.
  • an aminopropyl column is used.
  • one of the buffers used as an eluting buffer comprises ammonium acetate.
  • mass spectrometry is used to identify and quantitate the compounds of the invention.
  • MS/MS is used to quantitate peaks isolated by liquid chromatography (see Bajad et al, Journal of Chromatography A, 1125(2006) 76-88).
  • isotopically labeled internal standards are used to quantify each compound of interest.
  • any of the cofactors or mevalonate pathway metabolites, or any combination of cofactors, CoA and non-CoA mevalonate pathway metabolites are quantitated with a relative standard deviation of less than 30%, 25%, 20%, 17%, 13% or 10%.
  • the RSD is less than 13%.
  • the RSD is less than 30%.
  • Relative standard deviation may refer to values measured from samples produced from the same extract. Alternatively, the relative standard deviation may refer to values measured from samples produced from different extracts.
  • an extract from a cell comprising: a cofactor and a mevalonate pathway metabolite, wherein the extract exhibits a pH value greater than about 9 and comprises an alcohol, and wherein the cofactor and the metabolite are stable in said extract for at least about 8 hours.
  • the cofactor and the metabolite may also be stable in said extract for at least about 12 hours.
  • the alcohol is methanol.
  • a fermentation method comprising: (a) initiating a first fermentation reaction comprising a medium and a population of host cells under an initial fermentation condition suitable for producing an isoprenoid from mevalonate pathway; (b) simultaneously quantitating a cofactor and a mevalonate pathway metabolite from the first fermentation reaction, wherein said cofactor and said metabolite are produced by said host cells; (c) performing a second fermentation reaction wherein one or more parameters of the initial fermentation condition used during the first fermentation reaction is adjusted based on the amount of said cofactor and/or said metabolite quantitated in (b).
  • the one or more parameters of (c) support production of said isoprenoid at a level higher than that produced under said initial fermentation condition.
  • the cell is prokaryotic or bacterial.
  • the cell is eukaryotic.
  • the cell can be a yeast cell.
  • the isoprenoid may be, for example, an alcohol.
  • the isoprenoid is a combustible molecule.
  • the methods of the invention may be used in combination with other methods of determining an enzymatic activity of a given pathway enzyme or concentration of certain mevalonate pathway metabolites.
  • the enzymatic activity can be ascertained by the formation of the product or conversion of a substrate of an enzymatic reaction that is under investigation.
  • the reaction can take place in vitro or in vivo.
  • the relative activity of HMG-CoA reductase and HMG-CoA synthase in a cell can be measured by the steady state level of HMG-CoA in a cell.
  • HMG-CoA can be extracted by Tricholoroacetic Acid (TCA), followed by analyzing the extracted material via Liquid Chromatography/Mass Spectrometry.
  • TCA Tricholoroacetic Acid
  • mevalonate kinase The activity of mevalonate kinase can be demonstrated by the formation of mevalonate 5-phosphate.
  • the relative activity of mevalonate kinase and HMG-CoA reductase can be measured by the steady state level of mevalonate, which can be determined by Gas Chromatography/Mass spectrometry. See e.g., WO05033287, which is incorporated herein by reference.
  • the present invention provides fermentation methods comprising initiating a fermentation reaction comprising a medium and a population of host cells under an initial fermentation condition suitable for producing an isoprenoid from the mevalonate pathway, quantitating simultaneously a cofactor and a mevalonate pathway metabolite produced by the host cells, and subsequently adjusting one or more parameters of the initial fermentation condition based on the amount, relative ratio or concentration of any cofactors and/or metabolites quantitated.
  • Parameters of fermentation condition which may be adjusted or left unchanged include, but are not limited to, selection of medium, medium supplements, nutrients, vitamins, minerals, nitrogen or CO 2 content, temperature, feed rate, choice of reactor, choice of organism to be used as host cell, and duration of incubation. Genetic modification is also encompassed as such a parameter, and any of the methods and biological molecules for engineering pathways discussed in this application may be employed. In one embodiment, any parameter may be modified which can affect the yield or efficiency of production of an isoprenoid compound, or which may result in a fermentation condition which is superior to the initial condition. In one such embodiment, such a parameter supports production of an isoprenoid at a level which is higher than that shown under initial fermentation conditions.
  • the host cell expresses a nucleic acid sequence encoding a mevalonate pathway enzyme from a prokaryote having an endogenous mevalonate pathway.
  • suitable prokaryotes include those from the genera: Actinoplanes; Archaeoglobus; Bdellovibrio; Borrelia; Chloroflexus; Enterococcus; Lactobacillus; Listeria; Oceanobacillus; Paracoccus; Pseudomonas; Staphylococcus; Streptococcus; Streptomyces; Thermoplasma ; and Vibrio .
  • Non-limiting examples of specific strains include: Archaeoglobus fulgidus; Bdellovibrio bacteriovorus; Borrelia burgdorferi; Chloroflexus aurantiacus; Enterococcus faecalis; Enterococcus faecium; Lactobacillus johnsonii; Lactobacillus plantarum; Lactococcus lactis; Listeria innocua; Listeria monocytogenes; Oceanobacillus iheyensis; Paracoccus zeaxanthinifaciens; Pseudomonas mevalonii; Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus haemolyticus; Streptococcus agalactiae; Streptomyces griseolosporeus; Streptococcus mutans; Streptococcus pneumoniae; Streptococcus pyogene
  • nucleic acid sequence encoding a mevalonate pathway enzyme is selected from acetyl-CoA thiolase, HMG-CoA synthase, HMG-CoA reductase, and mevalonate kinase.
  • nucleic acid sequence encoding a mevalonate pathway enzyme is selected from acetyl-CoA thiolase, HMG-CoA synthase, HMG-CoA reductase, and mevalonate kinase and is from a prokaryote belonging to the genus Enterococcus or the genus Pseudomonas or the genus Staphylococcus .
  • the nucleic acid sequence encoding a mevalonate pathway enzyme is selected from acetyl-CoA thiolase, HMG-CoA synthase, HMG-CoA reductase, and mevalonate kinase and is from Enterococcus faecalis or from Staphyloccoccus aureus.
  • nucleic acid sequence encoding a mevalonate pathway enzyme is a Class II HMG-CoA reductase.
  • HMG-CoA reductases are generally classified into two classes, which are distinguishable based on sequence homology and/or enzymatic properties (see, for example, Hedl, et al., J. Bacteriology, 1927-1932, 2004, and Bochar, et al., Molec. Genet. Metab., 66, 122-127, 1999).
  • a prototypical Class II HMG-CoA reductase is derived from Pseudomonas mevalonii .
  • variant Class II HMG-CoA reductases exhibiting at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 80%, 90%, or 95% identity as compared to the amino acid sequence of P. mevalonii HMG-CoA reductase.
  • the identities of amino acid sequences can be determined by the methods described in Bochar, et al., Molec. Genet. Metab., 66, 122-127, 1999.
  • Non-limiting exemplary Class II HMG-CoA reductases include those derived from HMG-CoA reductases from: Archaeoglobus fulgidus (NC — 000917); Bdellovibrio bacteriovorus (BX842650); Borrelia burgdorferi (AE001169); Chloroflexus aurantiacus (AJ299212); Enterococcus faecalis (AAO81155); Enterococcus faecium (AF290094); Lactobacillus johnsonii (AE017204); Lactobacillus plantarum; Lactococcus lactis (AE006387); Listeria innocua (CAC96053); Listeria monocytogenes (AE017324); Oceanobacillus iheyensis (NC — 000917); Paracoccus zeaxanthinifaciens (AJ431696); Pseudomonas mevalonii (M24015);
  • the host cells are cultured in a fermentation medium comprises a carbon source present in an amount that is lower than that which would provide for a maximum specific growth rate.
  • the host cells are cultured in a medium where the carbon source is maintained at a level to provide for less than about 90%, 80%, 75%, 60%, 50%, 40%, 30%, 25%, 20%, 10%, 5%, 1%, or less, of the maximum specific growth rate. Any carbon-containing sources that are digestible by the microorganism can be used.
  • Non-limiting examples include carbohydrates such as monosaccharides, oligosaccharides and polysaccharides, organic acids such as acetic acid, propionic acid; and alcohols such as ethanol and propanol, and polyols such as glycerol.
  • the carbon sources comprise primarily monosaccharides or oligosaccharides. In other embodiments, the carbon source consists essentially of monosaccharides and disaccharides. In still other embodiments, the carbon source is essentially free of cellulose.
  • Monosaccharides are the simple sugars that serve as building blocks for carbohydrates. They are classified based on their backbone of carbon (C) atoms: trioses have three carbon atoms, tetroses four, pentoses five, hexoses six, and heptoses seven. The carbon atoms are bonded to hydrogen atoms (—H), hydroxyl groups (—OH), and carbonyl groups (—C ⁇ O), whose combinations, order, and configurations allow a large number of stereoisomers to exist.
  • Pentoses include xylose, found in woody materials; arabinose, found in gums from conifers; ribose, a component of RNA and several vitamins, and deoxyribose, a component of DNA.
  • Exemplary hexoses include glucose, galactose, and fructose.
  • Monosaccharides combine with each other and other groups to form a variety of disaccharides, and oligosaccharides.
  • An oligosaccharide is a saccharide polymer containing a small number (typically three to ten) of simple sugars. They are generally found either O- or N-linked to compatible amino acid side chains in proteins or lipid moieties.
  • a preferred oligosaccharide for use in the present fermentation reaction is disaccharide, including for example, sucrose, or trisaccharide such as raffinose.
  • these polysaccharides can be first converted into monosaccharides and oligosaccharides by chemical means or by enzymatic methods.
  • cellulose can be converted into glucose by the enzyme cellulase.
  • polysaccharides such as cellulose found in the biomass (including e.g., canola, alfalfa, rice, rye, sorghum, sunflower, wheat, soybean, tobacco, potato, peanut, cotton, sweet potato, cassava, coffee, coconut, citrus trees, cocoa, tea, fruits such as, banana, fig, pineapple, guava, mango, oats, barley, vegetables, ornamentals, or conifers) is used as the ultimate carbon source, it can be digested by cellulase to generate simpler sugars for use in conjunction with the fermentation procedure of the present invention.
  • cellulose found in the biomass including e.g., canola, alfalfa, rice, rye, sorghum, sunflower, wheat, soybean, tobacco, potato, peanut, cotton, sweet potato, cassava, coffee, coconut, citrus trees, cocoa, tea, fruits such as, banana, fig, pineapple, guava, mango, oats, barley, vegetables, ornamentals, or conifers
  • the monosaccharide and/or oligosaccharide constitute at least about 50% by weight of the carbon source as determined at the beginning of the fermentation. In other embodiments, the monosaccharide and/or oligosaccharide constitute at least about 80% or even 90% by weight of the carbon source as determined at the beginning of the fermentation, such that the fermentation medium is essentially free of cellulose.
  • the host cells are cultured in a fermentation medium comprises a nitrogen source.
  • Sources of assimilable nitrogen that can be used in a suitable fermentation reaction mixture include, but are not limited to, simple nitrogen sources, organic nitrogen sources, and complex nitrogen sources.
  • Such nitrogen sources include anhydrous ammonia, ammonium salts of inorganic or organic acids such as ammonium chloride, ammonium sulfate, ammonium acetate, ammonium phosphate, other nitrogen-containing compounds and substances of animal, vegetable, and/or microbial origin.
  • Amino acids can also be used as the nitrogen source, including leucine, isoleucine or valine, or a mixture thereof.
  • the fermentation reaction is given an initial bolus of carbon source sufficient to grow at or near the maximum specific growth rate (unlimited growth) followed by a reduced feed rate at a level below that required to support the maximum specific growth rate, for the remainder of the fermentation.
  • the point at which the reduced carbon source feed rate is implemented is the point at which a predetermined feed rate is achieved.
  • the microorganism is provided with enough carbon source to grow exponentially to a feed rate of about 15 g/L/hr, after which the feed rate is reduced to 5.7 g/L/hr and held constant at that rate for the remainder of the fermentation.
  • one or more of the heterologous mevalonate pathway enzymes is inducible and induced after the carbon source feed rate has been reduced to a level below that required for maximum specific growth.
  • the fermentation is first run by adding carbon source to achieve a exponential growth, but at a level which is below that to support maximum specific growth, then the carbon source feed rate is reduced to an even lower level for the remainder of the fermentation, and the inducer added after the carbon source feed rate is reduced.
  • the microorganisms are induced with isopropylthio-beta-D-galactoside (IPTG) after the reduced carbon source feed is initiated.
  • IPTG isopropylthio-beta-D-galactoside
  • the fermentation reaction is performed in a manner that avoids the build up of toxic substances that decrease cell growth rates.
  • toxic products such as acetate can build up in the organism. See, for example, Kortz et al. (1995) J. Biotechnol. 39: 59-65.
  • the level at which the carbon source is added below the level where the toxic products do not accumulate is referred to as the critical level or the inhibitory threshold.
  • the fermentation reaction is performed such that the carbon source is kept below the critical level for the build up of toxic substances.
  • the critical concentration of substrates will vary with the strain and the medium which is used.
  • An effective fermentation reaction mixture can contain other compounds such as inorganic salts, vitamins, trace metals, or growth promoters. Such other compounds can also be present in carbon, nitrogen or mineral sources in the effective reaction mixture or can be added specifically to the reaction mixture.
  • One embodiment of the invention involves providing these compounds at levels that are suboptimal as compared to that would support the maximum growth rate of the host cells in order to increase isoprenoid production.
  • the fermentation reaction mixture can also contain a suitable phosphate source.
  • phosphate sources include both inorganic and organic phosphate sources.
  • Non-limiting examples of phosphate sources include, but are not limited to, phosphate salts such as mono or dibasic sodium and potassium phosphates, ammonium phosphate, polyphosphate, and mixtures thereof.
  • a suitable fermentation reaction mixture can also include a source of magnesium.
  • the magnesium is in the form of a physiologically acceptable salt, such as magnesium sulfate heptahydrate, although other magnesium sources in concentrations that contribute similar amounts of magnesium can be used. Further, in some instances it may be desirable to allow the fermentation reaction mixture to become depleted of a magnesium source during fermentation.
  • the fermentation reaction mixture can also include a biologically acceptable chelating agent, such as the dihydrate of trisodium citrate and ethylenediaminetetraacetic acid.
  • the fermentation reaction mixture can also initially include a biologically acceptable acid or base to maintain the desired pH of the fermentation reaction mixture.
  • Biologically acceptable acids include, but are not limited to, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid and mixtures thereof.
  • Biologically acceptable bases include, but are not limited to, ammonium hydroxide, sodium hydroxide, potassium hydroxide and mixtures thereof.
  • the fermentation reaction mixture can also include a biologically acceptable calcium source, including, but not limited to, calcium chloride.
  • the fermentation reaction mixture can also include sodium chloride.
  • the fermentation reaction mixture can also include trace metals.
  • trace metals can be added to the fermentation reaction mixture as a stock solution that, for convenience, can be prepared separately from the rest of the fermentation reaction mixture.
  • a suitable trace metals solution can include, but is not limited to sodium selenate; ferrous sulfate; heptahydrate; cupric sulfate, pentahydrate; zinc sulfate, heptahydrate; sodium molybdate, dihydrate; cobaltous chloride; selenium or chromium solution; hexahydrate; and manganous sulfate monohydrate.
  • Hydrochloric acid may be added to the stock solution to keep the trace metal salts in solution.
  • the intermediate or compound is typically present in an excess amount.
  • Fermentation can be conducted under anaerobic (deficient in oxygen) or aerobic (oxygenated) conditions. Under aerobic conditions, microorganisms can break down sugars to end products such as CO 2 and H 2 O. Under anaerobic conditions, the host cells utilize an alternative pathway to produce CO 2 and ethanol. Fermentation can also be used to refer to the bulk growth of microorganisms on a growth medium where no distinction is made between aerobic and anaerobic metabolism. In general, aerobic fermentation is carried out for production of isoprenoids.
  • the fermentations of the present invention can be carried out in a batch, a fed-batch, or a continuous process.
  • a batch process is typically a closed process where all of the raw materials are added at the beginning of the fermentation.
  • a fed-batch process is typically a closed process where the carbon source and/or other substrates are added in increments throughout the process.
  • a fed-batch process allows for greater control of the medium and the growth of the microorganisms.
  • a continuous process can be considered an open system where medium is continuously added and product is simultaneously removed. Processes in between these types can also be used. For instance, in one embodiment, the fermentation is begun as a fed-batch process, and an organic layer, such as dodecane is placed in contact with the fermentation medium while the fermentation process continues.
  • Isoprenoids which typically have a higher solubility in the organic medium than in the aqueous fermentation medium are extracted out of the fermentation medium into the organic layer. Where the isoprenoids are produced in excess of the saturation point and form a layer separable from the medium, then simple separation by way of draining or sucking the distinct phase layer can be carried out.
  • This process has characteristics of both a fed-batch process and a continuous process, because of the removal of product from the medium and the fermentation progresses.
  • the fed-batch and continuous processes allow for the control of the addition of fermentation components during the fermentation process.
  • a fed-batch, continuous, or combination of these processes is usually preferred in carrying out the invention. These processes allow for greater control of the rate of addition of feed and other fermentation components as a function of time.
  • the removal of product during fermentation can be beneficial, especially where the accumulated product leads to inhibition of the production pathways.
  • the amount of microorganism per liter of fermentation, or the density of microorganism can be measured by measuring the weight of microorganism isolated from a given volume of the fermentation medium.
  • a common measure is the dry weight of cells per liter of fermentation medium.
  • Another method which can be used to monitor the fermentation while it is progressing is by a measurement of the optical density of the medium.
  • a common method is to measure the optical density at a wavelength of 600 nm, referred to the OD 600 , or the OD.
  • the OD can be correlated to a the density of a specific type of organism within a specific medium, but the specific relationship between OD and amount of microorganism per volume will not generally be applicable across all types of organisms in all types of media.
  • a calibration curve can be created by measuring the OD and the dry cell weight over a range of cell densities. In some cases, these correlations can be used in different fermentation of the same or similar microorganisms in the same or similar media.
  • the subject fermentation methods are suitable for producing a wide variety of isoprenoids.
  • Non-limiting examples of suitable isoprenoids include: hemiterpenes (derived from 1 isoprene unit) such as isoprene; monoterpenes (derived from 2 isoprene units) such as myrcene; sesquiterpenes (derived from 3 isoprene units) such as amorpha-4,11-diene; diterpenes (derived from four isoprene units) such as taxadiene; triterpenes (derived from 6 isoprene units) squalene; tetraterpenes (derived from 8 isoprenoids) ⁇ -carotene; and polyterpenes (derived from more than 8 isoprene units) such as polyisoprene.
  • the isoprenoid is not a carotenoid.
  • the isoprenoid is a C 5 -C 20 isoprenoid.
  • C 5 compounds may be derived from IPP or DMAPP. These compounds are also known as hemiterpenes because they are derived from a single isoprene unit (IPP or DMAPP).
  • C 10 compounds may be derived from geranyl pyrophosphate (GPP), which is made by the condensation of IPP with DMAPP.
  • GPP geranyl pyrophosphate
  • An enzyme known to catalyze this step is, for example, geranyl pyrophosphate synthase.
  • C 10 compounds are also known as monoterpenes because they are derived from two isoprene units. GPP can be further processed to a monoterpene.GPP is then subsequently converted to a variety of C 10 compounds.
  • Illustrative examples of C 10 compounds include but are not limited to:
  • Carene is made from GPP from carene synthase.
  • Geraniol also known as rhodnol
  • Geraniol is the main component of oil-of-rose and palmarosa oil. It also occurs in geranium, lemon, and citronella. Geraniol is made from GPP by geraniol synthase.
  • Linalool whose structure is
  • Linalool is made from GPP by linalool synthase.
  • Limonene is made from GPP by limonene synthase.
  • Myrcene is made from GPP by myrcene synthase.
  • ⁇ -Pinene is made from GPP by ⁇ -pinene synthase. ⁇ -Pinene
  • ⁇ -Pinene is made from GPP by ⁇ -pinene synthase.
  • ⁇ -terpinene is made from GPP by a ⁇ -terpinenesynthase.
  • Terpinolene is made from GPP by terpinolene synthase.
  • C 15 compounds may be derived from farnesyl pyrophosphate (FPP) which is made by the condensation of two molecules of IPP with one molecule of DMAPP.
  • FPP farnesyl pyrophosphate
  • An enzyme known to catalyze this step is, for example, farnesyl pyrophosphate synthase.
  • C 15 compounds are also known as sesquiterpenes because they are derived from three isoprene units.
  • Illustrative examples of C 15 compounds include but are not limited to:
  • Amorphadiene is made from FPP by amorphadiene synthase.
  • ⁇ -Farnesene is made from FPP by ⁇ -farnesene synthase.
  • ⁇ -farnesene is synthesized as a natural insect repellent.
  • ⁇ -Farnesene is made from FPP by ⁇ -farnesene synthase.
  • Farnesol is made from FPP by a hydroxylase such as farnesol synthase.
  • Nerolidol is made from FPP by a hydroxylase such as nerolidol synthase.
  • Patchouli alcohol is also known as patchouli alcohol and is a constituent of the essential oil of Pogostemon patchouli .
  • Patchouliol is made from FPP by patchouliol synthase.
  • Valencene is made from FPP by nootkatone synthase.
  • C 20 compounds may be derived from geranylgeraniol pyrophosphate (GGPP) which is made by the condensation of three molecules of IPP with one molecule of DMAPP.
  • An enzyme known to catalyze this step is, for example, geranylgeranyl pyrophosphate synthase.
  • C 20 compounds are also known as diterpenes because they are derived from four isoprene units.
  • GGPP can be further processed to a diterpene, or can be further processed to produce a carotenoid.
  • GGPP can also be made by adding IPP to FPP. GGPP is then subsequently converted to a variety of C 20 isoprenoids.
  • Illustrative examples of C 20 compounds include but are not limited to:
  • Geranylgeraniol is a constituent of wood oil from Cedrela toona and of linseed oil. Geranylgeraniol can be made by e.g., adding to the expression constructs a phosphatase gene after the gene for a GGPP synthase.
  • Abietadiene encompasses the following isomers:
  • Abietadiene is made by abietadiene synthase.
  • Illustrative examples of C 20+ compounds include sesterterpenes (C 25 compound made from five isoprene units), triterpenes (C 30 compounds made from six isoprene units), and tetraterpenes (C 40 compound made from eight isoprene units).
  • the fermentation methods of the invention may be used in the production of a combustible isoprenoid.
  • the isoprenoid compounds described herein may, for example, be used as combustible materials or fuels.
  • the fermentation methods of the invention comprise adjusting a parameter of the initial fermentation condition by engineering MEV pathways to enhance production of isoprenoids in a host cell.
  • the pathway is typically engineered via recombinant DNA technology by expressing heterologous sequences encoding enzymes in the pathway.
  • the activity of a MEV pathway enzyme in a host can be altered in a number of ways, including, but not limited to, expressing a modified form of the enzyme that exhibits increased solubility in the host cell, expressing an altered form of the enzyme that lacks a domain through which the activity of the enzyme is inhibited, expressing a modified form of the enzyme that has a higher K cat or a lower K m for the substrate, or expressing an altered form of the enzyme that is not affected by feed-back or feed-forward regulation by another molecule in the pathway.
  • variant enzymes can also be isolated through random mutagenesis of a broader specificity enzyme, as described below, and a nucleotide sequence encoding such variant enzyme can be expressed from an expression vector or from a recombinant gene integrated into the genome of a host microorganism.
  • the yield of an isoprenoid via one or more metabolic pathways disclosed herein can be augmented by inhibiting reactions that divert intermediates from productive steps towards formation of the isoprenoid product.
  • Inhibition of the unproductive reactions can be achieved by reducing the expression and/or activity of enzymes involved in one or more unproductive reactions.
  • Such reactions include side reactions of the TCA cycle that lead to fatty acid biosynthesis, alanine biosynthesis, the aspartate superpathway, gluconeogenesis, heme biosynthesis, and/or glutamate biosynthesis, at a level that affects the overall yield of an isoprenoid production.
  • the conversion of acetyl-CoA to acetate via the action of phosphotransacetylase is another example of unproductive side reaction.
  • “knocking out” or “knocking down” the pta gene that encodes phosphotransacetylase may also be carried in order to increase the yield of isoprenoid production.
  • “knocking out” or “knocking down” the pta gene that encodes phosphotransacetylase may also be carried in order to increase the yield of isoprenoid production.
  • one skilled in the art may choose to target additional unproductive steps.
  • carotenoid is the isoprenoid of choice
  • a reduced gene expression may be accomplished by deletion, mutation, and/or gene rearrangement. It can also be carried out with the use of antisense RNA, siRNA, miRNA, ribozymes, triple stranded DNA, and transcription and/or translation inhibitors.
  • transposons can be employed to disrupt gene expression, for example, by inserting it between the promoter and the coding region, or between two adjacent genes to inactivate one or both genes.
  • LC/MS/MS was used to evaluate a set of standards representing mevalonate pathway metabolites and co-factors. The objective was to verify that both the metabolites and co-factors can be detected using the desired LC/MS/MS procedure.
  • Ammonium Acetate Buffer ⁇ 38.5 g ammonium acetate was added to 500 mL of 1 M Ammonium acetate in LC/MS grade water. The mixture was transferred to a 500 mL graduated cylinder. Water was added to make up 500 mL and the buffer was stored at 4° C. for future use.
  • LC Solvent To a clean LC solvent bottle and fresh pipettes, 960 mL of LC/MS grade water, 20 mL of ammonium acetate solution, and 20 mL of ammonium hydroxide solution was added. After the additions, the solution was mixed well. 50 mL of solvent was removed and transferred to a 50 mL falcon tube and stored at 4° C. for preparation of the extraction buffer. 50 mL acetonitrile was added to the LC solvent and the solution was mixed again.
  • MeOH with Formic Acid 0.1 mL of 100% formic acid was added to 79.9 mL of LC/MS grade methanol and stored at 4° C.
  • Extraction Buffer 25 mL of LC solvent prepared above was added to 25 mL of LC/MS grade methanol. The solution was mixed well and stored at 4° C.
  • HPLC Parameters are shown in Table 1.
  • S. cerevisiae or E. coli was grown in either shake flasks or fermentors with or without isopropyl myristate overlay.
  • Cell samples from were extracted and mevalonate pathway metabolites and co-factors were analyzed using LC/MS/MS. The objective is to verify that intracellular mevalonate pathway metabolites and co-factors can be detected and that those metabolites and co-factors can be quantified.
  • Cell samples were prepared using a basic extraction method that allows for quantification of coA co-factors and other mevalonate pathway metabolites and co-factors. Using the LC/MS/MS procedure and results described in Example 1, intracellular metabolites and cofactors were identified and quantified. Linearity and reproducibility of the measured relative concentration was also evaluated.
  • the extraction procedure involves immediately quenching the harvested cells using ⁇ 80° C. methanol. The mixture is then centrifuged and supernatant is removed. The pellets are then re-suspended with extraction solvent and glass beads. The re-suspended pellets and glass beads are vortexed and then sonicated to break the cells open. The supernatant is collected and subsequent extractions can be performed to maximize recovery of the desired metabolites and co-factors. In some procedures, samples were immediately quenched with ⁇ 80° C. methanol. After methanol removal by centrifugation, analytes were extracted in 2 rounds with 20 mM ammonium acetate buffer, pH 9.4:methanol (50:50 v/v).
  • Extracts were analyzed by HILIC-MS/MS. Chromatography was performed on a Luna NH2 column (150 ⁇ 2.1, 3 ⁇ , Phenomenex) with solvent A (20 mM ammonium acetate buffer, pH 9.4) and solvent B (acetonitrile) with a gradient of 80% o 0% B in 25 min. Mass spectrometer (TSQ quantum ultra, ThermoFisher) was operated in MRM mode in both positive and negative ESI mode to cover all the metabolites and co-factors.
  • Extraction tubes were prepared by adding 1.6 mL of HPLC grade methanol to pre-induction samples or 0.8 mL of HPLC grade methanol to post-induction samples and then stored overnight at ⁇ 80° C.
  • An extraction buffer was prepared with internal standards by adding approximately 50 ⁇ l of internal standard mixture was to approximately 950 ⁇ L of extraction buffer. Extraction tubes were removed from ⁇ 80° C. and placed on dry ice.
  • sample 400 or 200 ⁇ l of sample (depending on whether it was a pre-induction sample or post-induction sample respectively) was added into extraction tubes. (The sample was poured directly into MeOH and not on the walls of the tube as it would freeze on walls, making it difficult to re-suspend the cells). The tube was inverted 6 times and then stored on dry ice. The sample was then centrifuged immediately (within 2 minutes) in a refrigerated ultracentrifuge at 9000 rcf for 2 minutes and then stored on dry ice. The supernatant was then removed and the pellet was stored on wet ice.
  • the pellet was then re-suspended in 400 ⁇ l of extraction solvent (pH 9.4) 20-25 glass beads were added to the re-suspended pellet and vortexed for 2 minutes.
  • the re-suspended pellet was stored on wet ice for 10 min, vortexed for 1 min and then further stored on wet ice for an additional 5 minutes.
  • the sample was sonicated for 3 minutes in cold water. After sonication, the sample was centrifuged in a refrigerated microcentrifuge at 9000 rcf for 3 minutes at 4° C. Supernatant was transferred to a labeled microcentrifuge tube. The pellet was re-suspended in 400 ⁇ l of extraction buffer (pH 9.4) by pipetting and vortexed for 2 minutes. The re-suspended pellet was stored on wet ice for 10 minutes, vortexed for 1 minute and then further stored on wet ice for an additional 5 minutes. After vortexing, the sample was sonicated for 3 minutes in cold water. After sonication, the sample was centrifuged in a refrigerated microcentrifuge at 9000 rcf for 3 minutes at 4° C. Supernatant was combined with the supernatant from the previous extraction.
  • extraction buffer pH 9.4
  • the an optional washing step can be added. This washing step could occur after the quenching reaction when the quenching mixture is centrifuged. A washing solvent such as chloroform can be added to the cell pellet. Alternatively, the washing step could occur prior to the basic supernatant is divided into aliquots for analysis. For example, an amount of cold chloroform can be added and then centrifuged. After centrifugation, the top most layer is removed and discarded. The supernatant can then be processed as previously described. This optional washing step allows for better reproducibility in samples where cells are grown in the presence of a hydrophobic overlay.
  • a hydrophobic overlay e.g. methyl oleate or isopropyl myristate
  • final extracts were stored at ⁇ 80° C. for 6 days.
  • the diluted (final methanol dilution) extracts were stored in eppendorf tubes (not the LC vials). On the day of analysis, the frozen diluted extracts were thawed on wet ice and centrifuged at 18,000 rcf for 4 minutes at 4° C. 250 ⁇ l of the sample was then transferred to LC vials.
  • the extraction method was performed at multiple conditions to achieve high stability and recovery of MEV pathway metabolites and co-factors. Efforts were made to ensure stability and recovery of CoA containing metabolites, non-coA containing metabolites, and co-factors.
  • FIGS. 4A-4B The effects of extraction solvent pH on recovery of metabolites and co-factors are shown in FIGS. 4A-4B . Higher recovery of several co-factors and metabolites, including NADH and FPP, were observed when a basic extraction buffer was used. A higher recovery level of both NADP and NADPH was observed when the broth to extraction solvent ratio was 1:2 (versus a 1:1 and 1:4). Higher recovery of the MEV pathway metabolites and co-factors was observed after two extractions using 50% methanol and 50% water with 20 mM ammonium acetate (pH 9.4) in comparison to a single extraction or three extractions.
  • FIG. 5 The stability of Acetyl-CoA, HMG-CoA, Mevalonate, FPP, ADP, ATP, NADH, FAD, and AcAc-CoA is shown over time in FIG. 5 .
  • the amount of AcAc-CoA recovered after 20 hours is significantly lower than after 0 hours.
  • the effect of formic acid addition to the extract for acidification is shown in FIG. 6 .
  • AcAc-CoA is stable in the acidified extract for at least 24 hours.
  • Quenching of cells was evaluated to ensure proper final temperature after addition of ⁇ 80° C. methanol to broth and to evaluate how much metabolite was lost due to the quenching process.
  • Temperature of a mixture of 30° C. water and ⁇ 80° C. methanol was measured after mixing ratios of water to methanol from 1:1 to 1:4. An optimal ratio for water to methanol was evaluated for recovery of MEV pathway metabolites and co-factors using LC/MS/MS.
  • Quenching of cells was evaluated to ensure proper final temperature after addition of ⁇ 80° C. methanol to broth and to evaluate how much metabolite was lost due to the quenching process.
  • Temperature of a mixture of 30° C. water and ⁇ 80° C. methanol was measured after mixing ratios of water to methanol from 1:1 to 1:4. An optimal ratio for water to methanol was evaluated for recovery of MEV pathway metabolites and co-factors using LC/MS/MS.
  • FIG. 7 shows the temperature of the sample for the various processing step.
  • Cell sampling was accomplished by quenching requisite amounts of yeast culture in ⁇ 80° C. solvent. For optical densities below 1.0 OD, 3 mL of broth was quenched in 12 mL solvent. For optical densities greater than 1.0 OD, 0.4 mL of broth was quenched in 1.6 mL solvent. Samples were immediately centrifuged at 4500 rpm for 3 minutes at ⁇ 7° C. for low OD, while high OD samples were centrifuged at 9000 rcf for 3 minutes at ⁇ 10° C. After centrifugation, supernatant was removed analyzed for potential intracellular metabolite leakage.
  • Sample pellets were kept on wet ice, where 200 ⁇ l internal standard spiked extraction buffer (50 ⁇ L internal standard per mL 20 mM ammonium acetate buffer) and glass beads were added and vortexed. Samples were sonicated in a wet ice bath for 3 minutes and placed on wet ice for 10 minutes, vortexed and subject to an additional 5 minutes on ice. Samples were then centrifuged at 9,000 rcf for 3 minutes, at 4° C. Extract was removed and the extraction procedure was repeated. Extract was pooled, diluted twice with methanol and analyzed by LCMSMS.
  • 200 ⁇ l internal standard spiked extraction buffer 50 ⁇ L internal standard per mL 20 mM ammonium acetate buffer
  • Samples were sonicated in a wet ice bath for 3 minutes and placed on wet ice for 10 minutes, vortexed and subject to an additional 5 minutes on ice. Samples were then centrifuged at 9,000 rcf for 3 minutes,
  • the best quenching solvent was determined to be 5% glycerol; 30% water; 65% methanol.
  • Prior art quenching solvents have described the use of buffered or un-buffered 60% methanol (at or below ⁇ 40° C.) which is a standard way of rapidly arresting metabolic activity.
  • quenching solvents that minimize such leakage have been explored.
  • one type of such solvents are glycerol-containing ones where glycerol is present in high concentrations (greater than 30%).
  • a commonly used example is 40% glycerol in Hepes buffer.
  • Methanol water combinations suffer from many of the same issues as glycerol saline combinations. Low freezing point and metabolite leakage prevent this from being a quenching solvent if one is interested in detecting a wide range of metabolites.
  • 100% methanol is an excellent quenching solvent under most circumstances, particularly in high cell density situations such as high density fermentations (optical density 600 30-200).
  • high cell density situations such as high density fermentations (optical density 600 30-200).
  • the metabolite signals are highly variable and there is significant ion suppression.
  • the addition of glycerol appears to improve signal detection by reducing ion suppression effect.
  • the signal intensity is significantly removed by less salt precipitation.
  • 5% glycerol is sufficient to avoid salt precipitation and significantly improve signal quality.
  • up to 20% glycerol can be used without introducing lengthy centrifugation step without significant adhering to sample vials.
  • the metabolites analyzed by this method using 5% glycerol; 30% water; 65% methanol as the quenching solvent include aminoacids, nucleoside bases, nucleosides, nucleoside monophosphates, nucleoside di/triphosphates, CoAs, carboxylic acids and redox-electron carriers and precursors.
  • the amino acids include: alanine, arginine, asparagines, glutamate, glutamine, histidine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine.
  • the nucleoside bases include: adenine, cytosine, guanine, and uracil.
  • the nucleosides include: adenosine, cytidine and guanosine.
  • the nucleoside monophosphates include: AMP, CMP, cyclic-AMP, dGMP, and GMP.
  • the nucleoside di/triphosphates include: ADP, ATP, CDP, CTP, GTP, TTP, and UDP.
  • the CoAs include: HMG-CoA, acetoacetyl CoA, acetyl-CoA, CoA, dephospho-CoA, and malonyl CoA.
  • the carboxylic acids include: citrate, fumarate, malate, and succinate.
  • the redox-electron-carriers and precursors include: FAD, FMN, NAD+, NADPH, oxidized glutathione, and reduced glutathione.
  • the sensitivity of the method of Example 1 could be improved by moving the analysis of certain metabolites from negative to positive mode.
  • Metabolites NAD, NADH, NADP, NADPH, ATP and ADP were moved from negative to positive mode ionization for mass spectrometry analysis.
  • Table 6 details the internal standards, metabolites and the mode of analysis.
  • FIGS. 10A-10B show the improved sensitivity of ATP, NADH, and NADPH when the method of analysis is switched from negative to positive mode.

Abstract

The present invention provides methods and compositions for monitoring cofactors and metabolites of a metabolic pathway of interest. The subject compositions and methods are particularly suited for monitoring the mevalonate pathway in a variety of cells. The invention also provides fermentation methods for the production of isoprenoids.

Description

    PRIOR RELATED APPLICATION
  • This application claims the benefit under 35. U.S.C. §119(e) of U.S. Provisional Application No. 61/063,258 filed Jan. 31, 2008 which is incorporated herein in its entirety.
  • BACKGROUND
  • Isoprenoids are ubiquitous in nature. They comprise a diverse family of over 40,000 individual products, many of which are vital to living organisms. Isoprenoids serve to maintain cellular fluidity, electron transport, and other metabolic functions. A vast number of natural and synthetic isoprenoids are useful as pharmaceuticals, cosmetics, perfumes, pigments and colorants, fungicides, antiseptics, nutraceuticals, and fine chemical intermediates.
  • An isoprenoid product is typically composed of repeating five carbon isopentenyl diphosphate (IPP) units, although irregular isoprenoids and polyterpenes have been reported. In nature, isoprenoids are synthesized by consecutive condensations of their precursor IPP and its isomer dimethylallyl pyrophosphate (DMAPP). Two pathways for these precursors are known. Eukaryotes, with the exception of plants, generally use the mevalonate-dependent (MEV) pathway to convert acetyl coenzyme A (acetyl-CoA) to IPP, which is subsequently isomerized to DMAPP. Prokaryotes, with some exceptions, typically employ only the mevalonate-independent or deoxyxylulose-5-phosphate (DXP) pathway to produce IPP and DMAPP. Plants use both the MEV pathway and the DXP pathway. See Rohmer et al. (1993) Biochem. J. 295:517-524; Lange et al. (2000) Proc. Natl. Acad. Sci. USA 97(24):13172-13177; Rohdich et al. (2002) Proc. Natl. Acad. Sci. USA 99:1158-1163.
  • Traditionally, isoprenoids have been manufactured by extraction from natural sources such as plants, microbes, and animals. However, the yield by way of extraction is usually very low due to a number of profound limitations. First, most isoprenoids accumulate in nature in only small amounts. Second, the source organisms in general are not amenable to the large-scale cultivation that is necessary to produce commercially viable quantities of a desired isoprenoid. Third, the requirement of certain toxic solvents for isoprenoid extraction necessitates special handling and disposal procedures, and thus complicating the commercial production of isoprenoids.
  • The elucidation of the MEV and DXP metabolic pathways has made biosynthetic production of isoprenoids feasible. For instance, microbes have been engineered to overexpress a part of or the entire mevalonate pathway for production of an isoprenoid named amorpha-4,11-diene (U.S. Pat. Nos. 7,172,886 and 7,192,751) Other efforts have focused on balancing the pool of glyceraldehyde-3-phosphate and pyruvate, or on increasing the expression of 1-deoxy-D-xylulose-5-phosphate synthase (dxs) and IPP isomerase (idi). See Farmer et al. (2001) Biotechnol. Prog. 17:57-61; Kajiwara et al. (1997) Biochem. J. 324:421-426; and Kim et al. (2001) Biotechnol. Bioeng. 72:408-415. Nevertheless, the conventional methods for monitoring and quantitation of metabolite levels in cells that utilize the mevalonate pathway suffer from a number of profound drawbacks. First, the conventional methods can only monitor a very limited number of the cofactors and metabolites involved in the mevalonate pathway. Second, this limitation is exacerbated by the fact that metabolites and individual cofactors of the pathway exhibit varying chemical stability profiles, which has made extraction and quantitation of more than several of such metabolites and cofactors difficult to achieve. There thus remains a need for methods and compositions useful for monitoring metabolic pathways such as the mevalonate pathway. The present invention addresses this need and provides related advantages as well.
  • SUMMARY OF THE INVENTION
  • The present invention provides compositions and methods related to the monitoring of mevalonate pathway metabolites. In one embodiment, the invention provides a method of quantitating a cofactor and a mevalonate pathway metabolite, comprising (a) providing an extract of a cell comprising said cofactor and said mevalonate pathway metabolite, wherein the extract exhibits a pH value of greater than about 7; and (b) quantitating said cofactor and said metabolite from said extract. In another embodiment, the invention provides a method of quantitating a cofactor and a mevalonate pathway metabolite, comprising (a) providing an extract of a cell comprising said cofactor and said mevalonate pathway metabolite, wherein the extract exhibits a pH value of greater than about 7; (b) dividing said extract of (a) into a plurality of aliquots, one of which being analyzed to quantitate individual metabolites of the mevalonate pathway except acetoacetyl-CoA, and to quantitate individual cofactors; and (c) adding an acid to at least one other aliquot, wherein said at least one other aliquot is analyzed to quantitate acetoacetyl CoA.
  • The cofactor may be selected from a first group consisting of NAD+, NADP+, NADH, NADPH, AMP, ADP, and ATP. The metabolite may be selected from a second group consisting of CoA metabolite and non-CoA metabolite. Non-CoA metabolites include farnesyl pyrophosphate, geranyl pyrophosphate, isopentenyl pyrophosphate, dimethylallyl pyrophosphate, mevalonate, mevalonate phosphate, and mevalonate pyrophosphate. CoA metabolites include acetyl CoA, acetoacetyl-CoA, and 3-hydroxy-3-methylglutaryl-CoA.
  • In some embodiments, the methods quantitate all cofactors and metabolites of the mevalonate pathway. In other embodiments, the step of quantitating is by mass spectrometry. For example, the step of quantitating may be by liquid chomatography in conjunction with mass spectrometry.
  • The invention also provides a method of quantitating all cofactors involved in the mevalonate pathway and all mevalonate pathway metabolites, comprising (a) providing an extract of a cell comprising said all cofactors and said all metabolites, wherein said extract comprises a buffer that stabilizes said cofactors and metabolites for at least about 8 hours; and (b) quantitating said all cofactors involved in the mevalonate pathway and said all metabolites from said extract. The cofactors may be NAD+, NADP+, NADH, NADPH, AMP, ADP, and ATP, and said all metabolites may be Acetyl CoA, Acetoacetyl-CoA, 3-hydroxy-3-methylglutaryl-CoA, farnesyl pyrophosphate, geranyl pyrophosphate, isopentenyl pyrophosphate, dimethylallyl pyrophosphate, mevalonate, mevalonate phosphate, and mevalonate pyrophosphate.
  • The invention also provides an extract from a cell comprising a cofactor and a mevalonate pathway metabolite, wherein the extract exhibits a pH value greater than about 9 and comprises an alcohol, and wherein the cofactor and the metabolite are stable in said extract for at least about 8 hours. The cofactor and the metabolite may also be stable in said extract for at least about 12 hours. In some cases, the alcohol is methanol. When desired, the extract is quenched at a temperature below 0° C. In certain embodiments, the extract is quenched at a temperature below −23° C.
  • Also provided herein is a fermentation method, comprising: (a) initiating a first fermentation reaction comprising a medium and a population of host cells under an initial fermentation condition suitable for producing an isoprenoid from mevalonate pathway; (b) simultaneously quantitating a cofactor and a mevalonate pathway metabolite from the first fermentation reaction, wherein said cofactor and said metabolite are produced by said host cells; (c) performing a second fermentation reaction wherein one or more parameters of the initial fermentation condition used during the first fermentation reaction is adjusted based on the amount of said cofactor and/or said metabolite quantitated in (b). In some embodiments, the one or more parameters of (c) support production of said isoprenoid at a level higher than that produced under said initial fermentation condition. In one embodiment, the cell is prokaryotic or bacterial. Alternatively, the cell is eukaryotic. For example, the cell can be a yeast cell. The isoprenoid may be, for example, an alcohol. In some embodiments, the isoprenoid is a hydrocarbon.
  • The present invention additionally describes a method of quantitating a plurality of types of mevalonate pathway metabolites, comprising: (a) providing an extract of a cell comprising said plurality of types of mevalonate pathway metabolites, wherein a first type of metabolite in said plurality is CoA mevalonate pathway metabolite selected from the group consisting of Acetyl-CoA, Acetoacetyl-CoA, and 3-hydroxy-3-methylglutaryl-CoA, and wherein a second type of metabolite in said plurality is non-CoA mevalonate pathway metabolite selected from the group consisting of farnesyl pyrophosphate, geranyl pyrophosphate, isopentenyl pyrophosphate, dimethylallyl pyrophosphate, mevalonate, mevalonate phosphate, and mevalonate pyrophosphate; and (b) quantitating said plurality of types of mevalonate pathway metabolites from said extract.
  • INCORPORATION BY REFERENCE
  • All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a schematic representation of the mevalonate (“MEV”) pathway for the production of isopentenyl pyrophosphate (“IPP”).
  • FIG. 2 is a schematic illustrating one embodiment of the inventive method comprising a quenching step; extraction step; and an optional washing step. The samples are divided into two aliquots which are treated in different manners for mass spectrometry analysis using positive and negative ionization modes. This allows for the detection and quantification of MEV pathway metabolites and co-factors.
  • FIGS. 3A-3C show LC/MS/MS data collected from MEV pathway standards and demonstrates detectability and defined peak shape for MEV pathway metabolites and co-factors.
  • FIGS. 4A-4C shows effects of using a basic, neutral, or acidic extraction buffer on recovery of intracellular metabolites and co-factors.
  • FIG. 5 shows stability of metabolites and co-factors in cell-extracts after extraction. As it can be seen, acetoacetyl CoA degrades with time.
  • FIG. 6 shows the stability of acetoacetyl CoA with and without extract acidification (e.g. such as by the addition of 0.1% formic acid (FA)).
  • FIG. 7 shows the effect of each processing step to the temperature (in Celsius) of the sample: Processing step I—quenching solvent on dry ice; II—solvent and broth at quenching; III—after 1 minute on dry ice; IV—after centrifugation at −10° C.; V—after extraction solvent was added; VI, sonication; VII—after 10 minutes on wet ice; VIII—after 5 minutes on wet ice; IX—after centrifugation at −4° C.
  • FIGS. 8A-8D illustrate the effects of the addition of water or glycerol or both to 100% methanol on the detection of representative intracellular metabolites. The best quenching solvent in this experiment was determined to be 65% methanol, 30% water and 5% glycerol.
  • FIG. 9 illustrate the effects of various amounts of glycerol to the detection of FAD and NAD. As it can be seen, better detection was observed with less than 40% glycerol (such as 20%, 10%, and 5%) than with 40% glycerol.
  • FIGS. 10A-10B compare the analysis of ATP, NADH and NADPH in negative and positive modes.
  • DETAILED DESCRIPTION OF THE INVENTION Definitions
  • Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Reference is made here to a number of terms that shall be defined to have the following meanings:
  • The term “optional” or “optionally” means that the subsequently described feature or structure may or may not be present, or that the subsequently described event or circumstance may or may not occur, and that the description includes instances where a particular feature or structure is present and instances where the feature or structure is absent, or instances where the event or circumstance occurs and instances where the event or circumstance does not occur.
  • The terms “metabolic pathway” is used herein to refer to a catabolic pathway or an anabolic pathway. Anabolic pathways involve constructing a larger molecule from smaller molecules, a process requiring energy. Catabolic pathways involve breaking down of larger molecules, often releasing energy. The term “mevalonate pathway” or “MEV pathway” is used herein to refer to the biosynthetic pathway that converts acetyl-CoA to IPP. The MEV pathway is illustrated schematically in FIG. 1.
  • The term “mevalonate pathway metabolite” includes precursors, intermediates and products of the mevalonate pathway. “CoA mevalonate pathway metabolites” include Acetyl-CoA, Acetoacetyl-CoA and 3-hydroxy-3-methylglutaryl-CoA. “Non-CoA mevalonate pathway metabolites” include other mevalonate pathway metabolites such as farnesyl pyrophosphate, geranyl pyrophosphate, isopentenyl pyrophosphate, dimethylallyl pyrophosphate, mevalonate, mevalonate phosphate, and mevalonate pyrophosphate.
  • The term “cofactor” refers to a nonprotein component which participates in an enzymatic reaction. Cofactors which are involved in the mevalonate pathway include, but are not limited to, adenosine monophosphate (AMP), adenosine diphosphate (ADP), adenosine triphosphate (ATP), nicotinamide adenine dinucleotide (NAD+, NADH) and nicotinamide adenine dinucleotide phosphate (NADP+, NADPH). Acetyl-CoA is both a cofactor and a CoA mevalonate pathway metabolite.
  • The term “extract” refers to a cell product obtained from a cell or collection of cells, for example a prokaryotic or eukaryotic cell culture. An extract may comprise intracellular and extracellular components of a cell, as well as parts of the fluid or solid medium in which the cell has been grown, as well as any buffers or additional reagents that may be used in the extraction procedure. Extracts are commonly liquids, solids, or may be liquids comprising solid fragments such as cellular fractions or precipitates.
  • The terms “cell”, “host cell” or “host microorganism” are used interchangeably. They refer to any archae, eukaryotic or prokaryotic organisms comprising at least part of the mevalonate pathway. Such organisms may be naturally occurring or may be genetically modified by insertion of a vector expressing a desired nucleic acid or polypeptide sequence or a vector comprising a sequence to alter the expression of a polypeptide endogenous to the host cell.
  • The term “aliquot” refers to a fraction of an extract isolated at any step during an extraction procedure.
  • The term “quantitate” refers to the action of measuring any relative or absolute concentration of a compound.
  • The term “relative standard deviation”, “RSD” or “% RSD” is a measure of the precision of an assay and represents to the absolute value of the coefficient of variation expressed as a percentage. It is generally calculated as RSD=(standard deviation of a range of samples)*100/(mean of range of samples).
  • The term “pH value” expresses the degree of acidity or basicity of a solution. In general, the term “acidifying” refers to a step in which an acidic solution is added to another solution to lower the initial pH value, resulting in a solution which may be acidic, neutral or even basic, depending on the amount of acidic solution added. Similary, “basifying” refers to a step in which a basic solution is added to another solution to raise the initial pH value, resulting in a solution which may be basic, neutral or even acidic, depending on the amount of basic solution added.
  • The word “pyrophosphate” is used interchangeably herein with “diphosphate”.
  • The term “endogenous” refers to a substance or process that occurs naturally, e.g., in a non-recombinant host cell.
  • The terms “nucleic acid” and “polynucleotide” are used interchangeably. They refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxynucleotides. Thus, this term includes, but is not limited to, single-, double-, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or a polymer comprising purine and pyrimidine bases or other natural, chemically, or biochemically modified, non-natural, or derivatized nucleotide bases.
  • The term “protein”, “polypeptides” and “peptides” are used interchangeably. They refer to a polymeric form of amino acids of any length, which can include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified peptide backbones.
  • The term “naturally occurring” as applied to a nucleic acid, an enzyme, a cell, or an organism, refers to a nucleic acid, enzyme, cell, or organism that is found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism that can be isolated from a source in nature and that has not been intentionally modified by a human in the laboratory is naturally occurring.
  • The terms “isoprenoid”, “isoprenoid compound”, “isoprenoid product”, “terpene”, “terpene compound”, “terpenoid”, and “terpenoid compound” are used interchangeably herein. They refer to compounds that are capable of being derived from IPP.
  • The singular forms “a,” “and,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an expression vector” includes a single expression vector as well as a plurality of expression vectors, and reference to “the host cell” includes reference to one or more host cells, and so forth. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.
  • Unless otherwise indicated, this invention is not limited to particular compounds, cofactors, intermediates, metabolites, enzymes, microorganisms, or processes, and as such may vary in accordance with the understanding of those of ordinary skill in the arts to which this invention pertains in view of the teaching herein. Terminology used herein is for purposes of describing particular embodiments only and is not intended to be limiting.
  • Cells
  • Any suitable cell may be used in the practice of the present invention. Illustrative examples of suitable cells include any archae, prokaryotic, or eukaryotic cell that comprises the entire or part of the mevalonate pathway. Examples of an archae cell include, but are not limited to those belonging to the genera: Aeropyrum, Archaeglobus, Halobacterium, Methanococcus, Methanobacterium, Pyrococcus, Sulfolobus, and Thermoplasma. Illustrative examples of archae strains include but are not limited to: Aeropyrum pernix, Archaeoglobus fulgidus, Methanococcus jannaschii, Methanobacterium thermoautotrophicum, Pyrococcus abyssi, Pyrococcus horikoshii, Thermoplasma acidophilum, Thermoplasma volcanium.
  • Examples of a procaryotic cell include, but are not limited to those belonging to the genera: Agrobacterium, Alicyclobacillus, Anabaena, Anacystis, Arthrobacter, Azobacter, Bacillus, Brevibacterium, Chromatium, Clostridium, Corynebacterium, Enterobacter, Erwinia, Escherichia, Lactobacillus, Lactococcus, Mesorhizobium, Methylobacterium, Microbacterium, Phormidium, Pseudomonas, Rhodobacter, Rhodopseudomonas, Rhodospirillum, Rhodococcus, Salmonella, Scenedesmun, Serratia, Shigella, Staphlococcus, Strepromyces, Synnecoccus, and Zymomonas.
  • Illustrative examples of prokaryotic bacterial strains include but are not limited to: Bacillus subtilis, Bacillus amyloliquefacines, Brevibacterium ammoniagenes, Brevibacterium immariophilum, Clostridium beigerinckii, Enterobacter sakazakii, Escherichia coli, Lactococcus lactis, Mesorhizobium loti, Pseudomonas aeruginosa, Pseudomonas mevalonii, Pseudomonas pudica, Rhodobacter capsulatus, Rhodobacter sphaeroides, Rhodospirillum rubrum, Salmonella enterica, Salmonella typhi, Salmonella typhimurium, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Staphylococcus aureus, and the like.
  • In general, if a bacterial host cell is used, a non-pathogenic strain is generally preferred. Illustrative examples of non-pathogenic strains include but are not limited to: Bacillus subtilis, Escherichia coli, Lactibacillus acidophilus, Lactobacillus helveticus, Pseudomonas aeruginosa, Pseudomonas mevalonii, Pseudomonas pudita, Rhodobacter sphaeroides, Rodobacter capsulatus, Rhodospirillum rubrum, and the like.
  • Examples of eukaryotic cells include but are not limited to fungal cells. Examples of fungal cell include, but are not limited to those belonging to the genera: Aspergillus, Candida, Chrysosporium, Cryotococcus, Fusarium, Kluyveromyces, Neotyphodium, Neurospora, Penicillium, Pichia, Saccharomyces, Trichoderma and Xanthophyllomyces (formerly Phaffia).
  • Illustrative examples of eukaryotic strains include but are not limited to: Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Candida albicans, Chrysosporium lucknowense, Fusarium graminearum, Fusarium venenatum, Kluyveromyces lactis, Neurospora crassa, Pichia angusta, Pichia finlandica, Pichia kodamae, Pichia membranaefaciens, Pichia methanolica, Pichia opuntiae, Pichia pastoris, Pichia pijperi, Pichia quercuum, Pichia salictaria, Pichia thermotolerans, Pichia trehalophila, Pichia stipitis, Streptomyces ambofaciens, Streptomyces aureofaciens, Streptomyces aureus, Saccaromyces bayanus, Saccaromyces boulardi, Saccharomyces cerevisiae, Streptomyces fungicidicus, Streptomyces griseochromogenes, Streptomyces griseus, Streptomyces lividans, Streptomyces olivogriseus, Streptomyces rameus, Streptomyces tanashiensis, Streptomyces vinaceus, Trichoderma reesei and Xanthophyllomyces dendrorhous (formerly Phaffia rhodozyma).
  • In general, if a eukaryotic cell is used, a non-pathogenic strain is preferred. Illustrative examples of non-pathogenic strains include but are not limited to: Fusarium graminearum, Fusarium venenatum, Pichia pastoris, Saccaromyces boulardi, and Saccaromyces cerevisiae.
  • In addition, certain strains have been designated by the Food and Drug Administration as GRAS or Generally Regarded As Safe. These strains include: Bacillus subtilis, Lactibacillus acidophilus, Lactobacillus helveticus, and Saccharomyces cerevisiae.
  • In one embodiment, the cell is a genetically modified host microorganism in which nucleic acid molecules have been inserted, deleted or modified (i.e., mutated; e.g., by insertion, deletion, substitution, and/or inversion of nucleotides), to either produce the desired isoprenoid compound or isoprenoid derivative, or effect an increased yield of the desired isoprenoid compound or isoprenoid derivative. In another embodiment, the host cell is capable of being grown in liquid growth medium. In contrast, a “control cell” is an alternative subject or sample used in an experiment for comparison purpose, and is typically a parental cell that does not contain the modification(s) made to a corresponding host cell.
  • Isoprenoid Pathways
  • In one embodiment, the cells of the present invention typically comprise or utilize the MEV pathway, and possibly the DXP pathway to synthesize IPP and its isomer, DMAPP. In general, eukaryotes other than plants use the MEV isoprenoid pathway exclusively to convert acetyl-CoA to IPP, which is subsequently isomerized to DMAPP. Prokaryotes, with some exceptions, use the mevalonate-independent or DXP pathway to produce IPP and DMAPP separately through a branch point. In general, plants use both the MEV and DXP pathways for IPP synthesis.
  • A schematic representation of the MEV pathway is described in FIG. 1. In the first step, two molecules of acetyl-coenzyme A are enzymatically combined to form acetoacetyl-CoA. An enzyme known to catalyze this step is, for example, acetyl-CoA thiolase (also known as acetyl-CoA acetyltransferase). In the second step of the MEV pathway, acetoacetyl-CoA is enzymatically condensed with another molecule of acetyl-CoA to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). An enzyme known to catalyze this step is, for example, HMG-CoA synthase. In the third step, HMG-CoA is enzymatically converted to mevalonate. An enzyme known to catalyze this step is, for example, HMG-CoA reductase. In the fourth step, mevalonate is enzymatically phosphorylated to form mevalonate 5-phosphate. An enzyme known to catalyze this step is, for example, mevalonate kinase.
  • In the fifth step, a second phosphate group is enzymatically added to mevalonate 5-phosphate to form mevalonate 5-pyrophosphate. An enzyme known to catalyze this step is, for example, phosphomevalonate kinase.
  • In the sixth step, mevalonate 5-pyrophosphate is enzymatically converted into IPP. An enzyme known to catalyze this step is, for example, mevalonate pyrophosphate decarboxylase. If IPP is to be converted to DMAPP, then a seventh step is required. An enzyme known to catalyze this step is, for example, IPP isomerase. If the conversion to DMAPP is required, an increased expression of IPP isomerase ensures that the conversion of IPP into DMAPP does not represent a rate-limiting step in the overall pathway.
  • In some embodiments, the host cell produces IPP via the MEV pathway, either exclusively or in combination with the DXP pathway. In other embodiments, a host's DXP pathway is functionally disabled so that the host cell produces IPP exclusively through a heterologously introduced MEV pathway. The DXP pathway can be functionally disabled by disabling gene expression or inactivating the function of one or more of the DXP pathway enzymes.
  • The metabolites DMAPP and IPP can undergo further reactions to produce additional metabolites. For example, the enzyme farnesyl pyrophosphate synthase can catalyze sequential condensation reactions of dimethylallyl pyrophosphate with 2 units of 3-isopentenyl pyrophosphate to form farnesyl pyrophosphate (FPP). In the first step, DMAPP may react with IPP to form geranyl pyrophosphate (GPP). Subsequently, one molecule of GPP may react with IPP to form one molecule of FPP. Below are described additional metabolites which may be produced by the mevalonate pathway.
  • Measurement of Cofactors and MEV Pathway Metabolites
  • The metabolites and the cofactors involved in the mevalonate pathway have a wide spectrum of physiochemical properties which makes quantification of these components problematic. For example, these compounds can be phosphorylated (mono, di, or tri) or non-phosphorylated. They also span the range from hydrophobic to hydrophilic. Certain metabolites such as isopentenyl pyrophosphate, dimethylallyl phyrophosphate, farnesyl pyrophosphate, NADPH and NADH are unstable in acidic solvents whereas ATP and CoAs are more stable in acidic solvents. Because of the complications involved, simultaneous analyses of these metabolites have not been previously attempted. Surprisingly, extraction of the cell metabolites in an extraction solvent with a pH greater than about 7, allows for the detection of all cofactors and metabolites.
  • Thus in one aspect, a method is provided comprising:
      • a. providing an extract of a cell comprising said cofactor and said mevalonate pathway metabolite, wherein the extract exhibits a pH value of greater than about 7; and
      • b. quantitating said cofactor and said metabolite from said extract.
  • In certain embodiments, the cell extract exhibits a pH value greater than or equal to about 8. In other embodiments, the cell extract exhibits a pH value greater than or equal to about 9. In still other embodiments, the cell extract exhibits a pH value greater than or equal to about 9.4.
  • In some embodiments, the cell extract exhibits a pH value of between 8 and 13. In some embodiments, the cell extract exhibits a pH value of between 8 and 11. In some embodiments, the cell extract exhibits a pH value of between 8 and 10. In some embodiments, the cell extract exhibits a pH value of between 9 and 13. In some embodiments, the cell extract exhibits a pH value of between 9 and 12. In some embodiments, the cell extract exhibits a pH value of between 9 and 11. In some embodiments, the cell extract exhibits a pH value of between 9 and 10.
  • In some embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value greater than about 7. In certain embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value greater than or equal to about 8. In other embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value greater than or equal to about 9. In still other embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value greater than or equal to about 9.4.
  • In some embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value of between 7 and 13. In some embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value of between 7 and 10. In some embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value of between 7 and 9. In some embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value of between 8 and 13. In some embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value of between 8 and 11. In some embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value of between 8 and 10. In some embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value of between 9 and 13. In some embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value of between 9 and 11. In some embodiments, the pH of the cell extract is due to the addition of an extraction solvent having a pH value of between 9 and 10.
  • In other embodiments, the extraction solvent comprises an alcohol and a basic buffer. In certain embodiments, the alcohol is a C1-C5 alcohol. In certain other embodiments, the alcohol is methanol or ethanol. Any suitable basic buffer can be used. Such a buffer may comprise cationic and anionic species such that the buffering capacity is sufficient around the desired pH. Illustrative examples of suitable cationic species include an ammonium salt such as ammonium chloride, ammonium acetate, and the like. The ratio of alcohol to basic buffer can be about 1. An illustrative example is a 1:1 solution of alcohol such as methanol to basic buffer such as ammonium acetate. In other embodiments, the ration of alcohol to basic buffer is greater than 2. An illustrative example is a solution comprising 70% methanol and 30% basic buffer such as ammonium acetate.
  • In one embodiment, the cofactor is NADH and/or NADPH. In another embodiment, the cofactor is ATP, ADP, AMP or any combination thereof. In still other embodiments, the mevalonate pathway metabolite is a CoA mevalonate pathway metabolite such as Acetyl-CoA, Acetoacetyl-CoA or 3-hydroxy-3-methylglutaryl-CoA. In yet another embodiment, the mevalonate pathway metabolite is Acetoacetyl-CoA or 3-hydroxy-3-methylglutaryl-CoA. In another embodiment, the mevalonate pathway metabolite is IPP or DMAPP. In yet another embodiment, the mevalonate pathway metabolite is mevalonate, mevalonate phosphate or mevalonate pyrophosphate. In still another embodiment, all cofactors from the group consisting of NAD+, NADP+, NADH, NADPH, AMP, ADP, and ATP are quantitated. In other embodiments, all metabolites from the group consisting of Acetyl-CoA, Acetoacetyl-CoA, 3-hydroxy-3-methylglutaryl-CoA, farnesyl pyrophosphate, geranyl pyrophosphate, isopentenyl pyrophosphate, dimethylallyl pyrophosphate, mevalonate, mevalonate phosphate, and mevalonate pyrophosphate are quantitated.
  • In another embodiment, the invention provides a method of quantitating a plurality of types of mevalonate pathway metabolites, including a first and second type of metabolites. The first type of metabolite may be a CoA mevalonate pathway metabolite, including Acetyl-CoA, Acetoacetyl-CoA, and 3-hydroxy-3-methylglutaryl-CoA, and the second type of metabolite may be a non-CoA mevalonate pathway metabolite, including farnesyl pyrophosphate, geranyl pyrophosphate, isopentenyl pyrophosphate, dimethylallyl pyrophosphate, mevalonate, mevalonate phosphate and mevalonate pyrophosphate.
  • In another aspect, a method is provided comprising:
      • a. quenching cell metabolism in a plurality of cells having at least one cofactor and metabolite by contacting the cells with a quenching solvent resulting in a first mixture, wherein the first mixture has a temperature that is equal to or less than about −25° C.;
      • b. adding an extraction solvent to the first mixture resulting in a second mixture wherein the pH of the second mixture has a pH value greater than about 7; and
      • c. quantitating said cofactor and said metabolite from the second mixture.
  • In some embodiments, the quenching solvent is a liquid at about −80° C. In other embodiments, the quenching solvent comprises methanol. In still other embodiments, the quenching solvent comprises methanol and glycerol. In certain other embodiments, the quenching solvent comprises methanol and glycerol and remains a liquid at −80° C.
  • In other embodiments, the temperature of the first mixture is less than about −23° C. In certain other embodiments, the temperature of the first mixture is equal to or less than about −30° C. In still other embodiments, the temperature of the first mixture is less than about −30° C.
  • In still other embodiments, the first mixture is centrifuged to separate the cells from the quenching solvent. When this is the case, the first mixture comprises the resulting cell pellet.
  • In certain embodiments, the second mixture exhibits a pH value greater than or equal to about 8. In other embodiments, the second mixture exhibits a pH value greater than or equal to about 9. In still other embodiments, the second mixture exhibits a pH value greater than or equal to about 9.4.
  • In certain embodiments, the second mixture exhibits a pH value between 8 and 13. In certain embodiments, the second mixture exhibits a pH value between 8 and 11. In certain embodiments, the second mixture exhibits a pH value between 8 and 10. In certain embodiments, the second mixture exhibits a pH value between 9 and 13. In certain embodiments, the second mixture exhibits a pH value between 9 and 11. In certain embodiments, the second mixture exhibits a pH value between 9 and 10.
  • In certain other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value greater than about 7. In certain embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value greater than or equal to about 8. In other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value greater than or equal to about 9. In still other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value greater than or equal to about 9.4.
  • In certain other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value between about 7 and 13. In certain other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value between about 7 and 11. In certain other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value between about 7 and 9. In certain other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value between about 8 and 13. In certain other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value between about 8 and 11. In certain other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value between about 8 and 10. In certain other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value between about 9 and 13. In certain other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value between about 9 and 11. In certain other embodiments, the pH of the second mixture is due to the addition of an extraction solvent having a pH value between about 9 and 10.
  • Additional processing steps to improve quantification include breaking open the cells to allow the cofactor and metabolite into the solution of the second mixture. Any method known in the art can be used to break open the cells such as vortexing and sonication or a combination of both. In some embodiments, glass beads can be used to facilitate by mechanical means to break open the cells. Other processing steps can include centrifugation to remove unwanted cell debris from the supernatant.
  • The second mixture can be divided into a plurality of aliquots so that each aliquot can be subsequently processed different to stabilize certain metabolites. As used herein, “stable” or “stabilized” refers to at least 50% of the initial concentration of a cofactor or metabolite remaining in an extract in a given time period. Cofactors and metabolites described in the invention are be stable for at least 1, 2, 3, 4, 5, 7, 8, 16, or 24 hours. In some embodiments, the cofactors involved in the mevalonate pathway and mevalonate pathway metabolites are stable for at least about 8 hours. In other embodiments, the cofactors and the metabolites are stable for at least about 12 hours.
  • In certain embodiments, at least one of these aliquots is acidified to stabilize CoAs and ATP. In other embodiments, at least one of these aliquots is acidified to stabilize CoAs. In still other embodiments, at least one of these aliquots is acidified to stabilize ATP. In yet other embodiments, at least one of these aliquots is acidified to stabilize acetoacetyl-CoA. Any suitable acid which can acidify an otherwise basic solution can be added to at least one of the aliquots of the second mixture. Prior to quantification, the plurality of aliquots can then be diluted as necessary with a suitable solvent such as methanol to optimize the concentrations of the cofactors and metabolites in the sample for analyses.
  • In another aspect, a method is provided comprising:
      • a. quenching cell metabolism in a plurality of cells having at least one cofactor and metabolite by contacting the cells with a quenching solvent resulting in a first mixture, wherein the first mixture has a temperature that is equal to or less than about −25° C.;
      • b. separating the cells from the supernatant in the first mixture resulting in a cell pellet;
      • c. isolating the cell pellet;
      • d. adding an extraction solvent to the cell pellet resulting in a second mixture wherein the pH of the second mixture has a pH value greater than about 8;
      • e. breaking open the cells in the second mixture;
      • f. separating the cell debris from the supernatant in the second mixture;
      • g. dividing the supernatant in the second mixture into at least two aliquots;
      • h. acidifying one of the at least two aliquots; and,
      • i. quantitating the at least one cofactor and metabolite in the at least two aliquots.
  • In some embodiments, the at least one cofactor and metabolite includes a CoA or ATP. In other embodiments, the at least one cofactor and metabolite includes a CoA. In still other embodiments, the at least one cofactor and metabolite includes acetoacetyl CoA.
  • Quantification may be by any method known in the art. In some embodiments, liquid chromatography is used.
  • Numerous elution buffers, columns and parameters are known in the art, and may be used to perform the method of the invention. In one embodiment, an aminopropyl column is used. In another embodiment, one of the buffers used as an eluting buffer comprises ammonium acetate.
  • In other embodiments, mass spectrometry is used to identify and quantitate the compounds of the invention. In certain embodiments, MS/MS is used to quantitate peaks isolated by liquid chromatography (see Bajad et al, Journal of Chromatography A, 1125(2006) 76-88). In still other embodiments, isotopically labeled internal standards are used to quantify each compound of interest.
  • In certain embodiments of the invention, any of the cofactors or mevalonate pathway metabolites, or any combination of cofactors, CoA and non-CoA mevalonate pathway metabolites are quantitated with a relative standard deviation of less than 30%, 25%, 20%, 17%, 13% or 10%. In other embodiments, the RSD is less than 13%. In still other embodiments, the RSD is less than 30%. Relative standard deviation may refer to values measured from samples produced from the same extract. Alternatively, the relative standard deviation may refer to values measured from samples produced from different extracts.
  • In another aspect, an extract from a cell is provided comprising: a cofactor and a mevalonate pathway metabolite, wherein the extract exhibits a pH value greater than about 9 and comprises an alcohol, and wherein the cofactor and the metabolite are stable in said extract for at least about 8 hours. The cofactor and the metabolite may also be stable in said extract for at least about 12 hours. In some cases, the alcohol is methanol. When desired, the extract is quenched at a temperature below 0° C. In certain embodiments, the extract is quenched at a temperature below −23° C.
  • In yet another aspect, a fermentation method is provided comprising: (a) initiating a first fermentation reaction comprising a medium and a population of host cells under an initial fermentation condition suitable for producing an isoprenoid from mevalonate pathway; (b) simultaneously quantitating a cofactor and a mevalonate pathway metabolite from the first fermentation reaction, wherein said cofactor and said metabolite are produced by said host cells; (c) performing a second fermentation reaction wherein one or more parameters of the initial fermentation condition used during the first fermentation reaction is adjusted based on the amount of said cofactor and/or said metabolite quantitated in (b). In some embodiments, the one or more parameters of (c) support production of said isoprenoid at a level higher than that produced under said initial fermentation condition. In one embodiment, the cell is prokaryotic or bacterial. Alternatively, the cell is eukaryotic. For example, the cell can be a yeast cell. The isoprenoid may be, for example, an alcohol. In some embodiments, the isoprenoid is a combustible molecule.
  • The methods of the invention may be used in combination with other methods of determining an enzymatic activity of a given pathway enzyme or concentration of certain mevalonate pathway metabolites. In general, the enzymatic activity can be ascertained by the formation of the product or conversion of a substrate of an enzymatic reaction that is under investigation. The reaction can take place in vitro or in vivo. For example, the relative activity of HMG-CoA reductase and HMG-CoA synthase in a cell can be measured by the steady state level of HMG-CoA in a cell. HMG-CoA can be extracted by Tricholoroacetic Acid (TCA), followed by analyzing the extracted material via Liquid Chromatography/Mass Spectrometry. The activity of mevalonate kinase can be demonstrated by the formation of mevalonate 5-phosphate. The relative activity of mevalonate kinase and HMG-CoA reductase can be measured by the steady state level of mevalonate, which can be determined by Gas Chromatography/Mass spectrometry. See e.g., WO05033287, which is incorporated herein by reference.
  • Fermentation
  • The present invention provides fermentation methods comprising initiating a fermentation reaction comprising a medium and a population of host cells under an initial fermentation condition suitable for producing an isoprenoid from the mevalonate pathway, quantitating simultaneously a cofactor and a mevalonate pathway metabolite produced by the host cells, and subsequently adjusting one or more parameters of the initial fermentation condition based on the amount, relative ratio or concentration of any cofactors and/or metabolites quantitated.
  • Parameters of fermentation condition which may be adjusted or left unchanged include, but are not limited to, selection of medium, medium supplements, nutrients, vitamins, minerals, nitrogen or CO2 content, temperature, feed rate, choice of reactor, choice of organism to be used as host cell, and duration of incubation. Genetic modification is also encompassed as such a parameter, and any of the methods and biological molecules for engineering pathways discussed in this application may be employed. In one embodiment, any parameter may be modified which can affect the yield or efficiency of production of an isoprenoid compound, or which may result in a fermentation condition which is superior to the initial condition. In one such embodiment, such a parameter supports production of an isoprenoid at a level which is higher than that shown under initial fermentation conditions.
  • Any cells described herein can be utilized in the subject fermentation method. In some embodiments, the host cell expresses a nucleic acid sequence encoding a mevalonate pathway enzyme from a prokaryote having an endogenous mevalonate pathway. Non-limiting examples of suitable prokaryotes include those from the genera: Actinoplanes; Archaeoglobus; Bdellovibrio; Borrelia; Chloroflexus; Enterococcus; Lactobacillus; Listeria; Oceanobacillus; Paracoccus; Pseudomonas; Staphylococcus; Streptococcus; Streptomyces; Thermoplasma; and Vibrio. Non-limiting examples of specific strains include: Archaeoglobus fulgidus; Bdellovibrio bacteriovorus; Borrelia burgdorferi; Chloroflexus aurantiacus; Enterococcus faecalis; Enterococcus faecium; Lactobacillus johnsonii; Lactobacillus plantarum; Lactococcus lactis; Listeria innocua; Listeria monocytogenes; Oceanobacillus iheyensis; Paracoccus zeaxanthinifaciens; Pseudomonas mevalonii; Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus haemolyticus; Streptococcus agalactiae; Streptomyces griseolosporeus; Streptococcus mutans; Streptococcus pneumoniae; Streptococcus pyogenes; Thermoplasma acidophilum; Thermoplasma volcanium; Vibrio cholerae; Vibrio parahaemolyticus; and Vibrio vulnificus;
  • In another embodiment, the nucleic acid sequence encoding a mevalonate pathway enzyme is selected from acetyl-CoA thiolase, HMG-CoA synthase, HMG-CoA reductase, and mevalonate kinase. In another embodiment, the nucleic acid sequence encoding a mevalonate pathway enzyme is selected from acetyl-CoA thiolase, HMG-CoA synthase, HMG-CoA reductase, and mevalonate kinase and is from a prokaryote belonging to the genus Enterococcus or the genus Pseudomonas or the genus Staphylococcus. In another embodiment, the nucleic acid sequence encoding a mevalonate pathway enzyme is selected from acetyl-CoA thiolase, HMG-CoA synthase, HMG-CoA reductase, and mevalonate kinase and is from Enterococcus faecalis or from Staphyloccoccus aureus.
  • In another embodiment, nucleic acid sequence encoding a mevalonate pathway enzyme is a Class II HMG-CoA reductase. HMG-CoA reductases are generally classified into two classes, which are distinguishable based on sequence homology and/or enzymatic properties (see, for example, Hedl, et al., J. Bacteriology, 1927-1932, 2004, and Bochar, et al., Molec. Genet. Metab., 66, 122-127, 1999).
  • A prototypical Class II HMG-CoA reductase is derived from Pseudomonas mevalonii. Also encompassed in the invention are variant Class II HMG-CoA reductases exhibiting at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 80%, 90%, or 95% identity as compared to the amino acid sequence of P. mevalonii HMG-CoA reductase. Further encompassed in the invention are variants having less than about 40%, 35%, 30%, 25%, 20%, or less, identity with an H. Sapiens HMG-CoA reductase. The identities of amino acid sequences can be determined by the methods described in Bochar, et al., Molec. Genet. Metab., 66, 122-127, 1999.
  • Non-limiting exemplary Class II HMG-CoA reductases include those derived from HMG-CoA reductases from: Archaeoglobus fulgidus (NC000917); Bdellovibrio bacteriovorus (BX842650); Borrelia burgdorferi (AE001169); Chloroflexus aurantiacus (AJ299212); Enterococcus faecalis (AAO81155); Enterococcus faecium (AF290094); Lactobacillus johnsonii (AE017204); Lactobacillus plantarum; Lactococcus lactis (AE006387); Listeria innocua (CAC96053); Listeria monocytogenes (AE017324); Oceanobacillus iheyensis (NC000917); Paracoccus zeaxanthinifaciens (AJ431696); Pseudomonas mevalonii (M24015); Staphylococcus aureus (AF290086); Staphylococcus epidermidis (AF290090); Staphylococcus haemolyticus (AF290088); Streptococcus agalactiae (CAD47046); Streptomyces griseolosporeus (AB037907); Streptococcus mutans (AAN58647); Streptococcus pneumoniae (AF290098); Streptococcus pyogenes (AF290096); Thermoplasma acidophilum (CAC11548); Thermoplasma volcanium (AL935253); Vibrio cholerae (AAF96622); Vibrio parahaemolyticus (BAC62311); and Vibrio vulnificus (AAO07090).
  • In other embodiments, the host cells are cultured in a fermentation medium comprises a carbon source present in an amount that is lower than that which would provide for a maximum specific growth rate. In certain embodiments, the host cells are cultured in a medium where the carbon source is maintained at a level to provide for less than about 90%, 80%, 75%, 60%, 50%, 40%, 30%, 25%, 20%, 10%, 5%, 1%, or less, of the maximum specific growth rate. Any carbon-containing sources that are digestible by the microorganism can be used. Non-limiting examples include carbohydrates such as monosaccharides, oligosaccharides and polysaccharides, organic acids such as acetic acid, propionic acid; and alcohols such as ethanol and propanol, and polyols such as glycerol.
  • In some embodiments, the carbon sources comprise primarily monosaccharides or oligosaccharides. In other embodiments, the carbon source consists essentially of monosaccharides and disaccharides. In still other embodiments, the carbon source is essentially free of cellulose.
  • Monosaccharides are the simple sugars that serve as building blocks for carbohydrates. They are classified based on their backbone of carbon (C) atoms: trioses have three carbon atoms, tetroses four, pentoses five, hexoses six, and heptoses seven. The carbon atoms are bonded to hydrogen atoms (—H), hydroxyl groups (—OH), and carbonyl groups (—C═O), whose combinations, order, and configurations allow a large number of stereoisomers to exist. Pentoses include xylose, found in woody materials; arabinose, found in gums from conifers; ribose, a component of RNA and several vitamins, and deoxyribose, a component of DNA. Exemplary hexoses include glucose, galactose, and fructose. Monosaccharides combine with each other and other groups to form a variety of disaccharides, and oligosaccharides. An oligosaccharide is a saccharide polymer containing a small number (typically three to ten) of simple sugars. They are generally found either O- or N-linked to compatible amino acid side chains in proteins or lipid moieties. A preferred oligosaccharide for use in the present fermentation reaction is disaccharide, including for example, sucrose, or trisaccharide such as raffinose.
  • Where it is desired to have cellulose, glycan, starch, or other polysaccharides as the ultimate carbon source, these polysaccharides can be first converted into monosaccharides and oligosaccharides by chemical means or by enzymatic methods. For instance, cellulose can be converted into glucose by the enzyme cellulase. Accordingly, if polysaccharides such as cellulose found in the biomass (including e.g., canola, alfalfa, rice, rye, sorghum, sunflower, wheat, soybean, tobacco, potato, peanut, cotton, sweet potato, cassava, coffee, coconut, citrus trees, cocoa, tea, fruits such as, banana, fig, pineapple, guava, mango, oats, barley, vegetables, ornamentals, or conifers) is used as the ultimate carbon source, it can be digested by cellulase to generate simpler sugars for use in conjunction with the fermentation procedure of the present invention. In certain embodiments, after the breakdown of the polysaccharide, the monosaccharide and/or oligosaccharide constitute at least about 50% by weight of the carbon source as determined at the beginning of the fermentation. In other embodiments, the monosaccharide and/or oligosaccharide constitute at least about 80% or even 90% by weight of the carbon source as determined at the beginning of the fermentation, such that the fermentation medium is essentially free of cellulose.
  • In other embodiments, the host cells are cultured in a fermentation medium comprises a nitrogen source. Sources of assimilable nitrogen that can be used in a suitable fermentation reaction mixture include, but are not limited to, simple nitrogen sources, organic nitrogen sources, and complex nitrogen sources. Such nitrogen sources include anhydrous ammonia, ammonium salts of inorganic or organic acids such as ammonium chloride, ammonium sulfate, ammonium acetate, ammonium phosphate, other nitrogen-containing compounds and substances of animal, vegetable, and/or microbial origin. Amino acids can also be used as the nitrogen source, including leucine, isoleucine or valine, or a mixture thereof.
  • In other embodiments, the fermentation reaction is given an initial bolus of carbon source sufficient to grow at or near the maximum specific growth rate (unlimited growth) followed by a reduced feed rate at a level below that required to support the maximum specific growth rate, for the remainder of the fermentation. In some cases, the point at which the reduced carbon source feed rate is implemented is the point at which a predetermined feed rate is achieved. In certain embodiments, the microorganism is provided with enough carbon source to grow exponentially to a feed rate of about 15 g/L/hr, after which the feed rate is reduced to 5.7 g/L/hr and held constant at that rate for the remainder of the fermentation.
  • In certain embodiments, one or more of the heterologous mevalonate pathway enzymes is inducible and induced after the carbon source feed rate has been reduced to a level below that required for maximum specific growth. For example, where the engineered microorganism has an inducible promoter, the fermentation is first run by adding carbon source to achieve a exponential growth, but at a level which is below that to support maximum specific growth, then the carbon source feed rate is reduced to an even lower level for the remainder of the fermentation, and the inducer added after the carbon source feed rate is reduced. In some embodiments, the microorganisms are induced with isopropylthio-beta-D-galactoside (IPTG) after the reduced carbon source feed is initiated.
  • In other embodiments, the fermentation reaction is performed in a manner that avoids the build up of toxic substances that decrease cell growth rates. For example, it is known that when too much glucose is added to the medium, toxic products such as acetate can build up in the organism. See, for example, Kortz et al. (1995) J. Biotechnol. 39: 59-65. Thus by providing a high level of carbon source, at or approaching the amount which would support a maximum growth rate (unlimited growth), the initial growth of the cells may be higher, but the growth becomes arrested due to the accumulation of toxic substances. The level at which the carbon source is added below the level where the toxic products do not accumulate is referred to as the critical level or the inhibitory threshold. Thus in certain embodiments, the fermentation reaction is performed such that the carbon source is kept below the critical level for the build up of toxic substances. Those skilled in the art will appreciate that the critical concentration of substrates will vary with the strain and the medium which is used.
  • An effective fermentation reaction mixture can contain other compounds such as inorganic salts, vitamins, trace metals, or growth promoters. Such other compounds can also be present in carbon, nitrogen or mineral sources in the effective reaction mixture or can be added specifically to the reaction mixture. One embodiment of the invention involves providing these compounds at levels that are suboptimal as compared to that would support the maximum growth rate of the host cells in order to increase isoprenoid production.
  • The fermentation reaction mixture can also contain a suitable phosphate source. Such phosphate sources include both inorganic and organic phosphate sources. Non-limiting examples of phosphate sources include, but are not limited to, phosphate salts such as mono or dibasic sodium and potassium phosphates, ammonium phosphate, polyphosphate, and mixtures thereof. A suitable fermentation reaction mixture can also include a source of magnesium. In some embodiments, the magnesium is in the form of a physiologically acceptable salt, such as magnesium sulfate heptahydrate, although other magnesium sources in concentrations that contribute similar amounts of magnesium can be used. Further, in some instances it may be desirable to allow the fermentation reaction mixture to become depleted of a magnesium source during fermentation.
  • The fermentation reaction mixture can also include a biologically acceptable chelating agent, such as the dihydrate of trisodium citrate and ethylenediaminetetraacetic acid. The fermentation reaction mixture can also initially include a biologically acceptable acid or base to maintain the desired pH of the fermentation reaction mixture. Biologically acceptable acids include, but are not limited to, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid and mixtures thereof. Biologically acceptable bases include, but are not limited to, ammonium hydroxide, sodium hydroxide, potassium hydroxide and mixtures thereof.
  • The fermentation reaction mixture can also include a biologically acceptable calcium source, including, but not limited to, calcium chloride. The fermentation reaction mixture can also include sodium chloride. The fermentation reaction mixture can also include trace metals. Such trace metals can be added to the fermentation reaction mixture as a stock solution that, for convenience, can be prepared separately from the rest of the fermentation reaction mixture. A suitable trace metals solution can include, but is not limited to sodium selenate; ferrous sulfate; heptahydrate; cupric sulfate, pentahydrate; zinc sulfate, heptahydrate; sodium molybdate, dihydrate; cobaltous chloride; selenium or chromium solution; hexahydrate; and manganous sulfate monohydrate. Hydrochloric acid may be added to the stock solution to keep the trace metal salts in solution.
  • If a pathway intermediate or a compound that can be converted to a pathway intermediate is added to the fermentation medium, the intermediate or compound is typically present in an excess amount.
  • Fermentation can be conducted under anaerobic (deficient in oxygen) or aerobic (oxygenated) conditions. Under aerobic conditions, microorganisms can break down sugars to end products such as CO2 and H2O. Under anaerobic conditions, the host cells utilize an alternative pathway to produce CO2 and ethanol. Fermentation can also be used to refer to the bulk growth of microorganisms on a growth medium where no distinction is made between aerobic and anaerobic metabolism. In general, aerobic fermentation is carried out for production of isoprenoids.
  • The fermentations of the present invention can be carried out in a batch, a fed-batch, or a continuous process. A batch process is typically a closed process where all of the raw materials are added at the beginning of the fermentation. A fed-batch process is typically a closed process where the carbon source and/or other substrates are added in increments throughout the process. A fed-batch process allows for greater control of the medium and the growth of the microorganisms. A continuous process can be considered an open system where medium is continuously added and product is simultaneously removed. Processes in between these types can also be used. For instance, in one embodiment, the fermentation is begun as a fed-batch process, and an organic layer, such as dodecane is placed in contact with the fermentation medium while the fermentation process continues. Isoprenoids, which typically have a higher solubility in the organic medium than in the aqueous fermentation medium are extracted out of the fermentation medium into the organic layer. Where the isoprenoids are produced in excess of the saturation point and form a layer separable from the medium, then simple separation by way of draining or sucking the distinct phase layer can be carried out. This process has characteristics of both a fed-batch process and a continuous process, because of the removal of product from the medium and the fermentation progresses. The fed-batch and continuous processes allow for the control of the addition of fermentation components during the fermentation process. A fed-batch, continuous, or combination of these processes is usually preferred in carrying out the invention. These processes allow for greater control of the rate of addition of feed and other fermentation components as a function of time. The removal of product during fermentation can be beneficial, especially where the accumulated product leads to inhibition of the production pathways.
  • The amount of microorganism per liter of fermentation, or the density of microorganism, can be measured by measuring the weight of microorganism isolated from a given volume of the fermentation medium. A common measure is the dry weight of cells per liter of fermentation medium. Another method which can be used to monitor the fermentation while it is progressing is by a measurement of the optical density of the medium. A common method is to measure the optical density at a wavelength of 600 nm, referred to the OD600, or the OD. The OD can be correlated to a the density of a specific type of organism within a specific medium, but the specific relationship between OD and amount of microorganism per volume will not generally be applicable across all types of organisms in all types of media. A calibration curve can be created by measuring the OD and the dry cell weight over a range of cell densities. In some cases, these correlations can be used in different fermentation of the same or similar microorganisms in the same or similar media.
  • The subject fermentation methods are suitable for producing a wide variety of isoprenoids.
  • Non-limiting examples of suitable isoprenoids include: hemiterpenes (derived from 1 isoprene unit) such as isoprene; monoterpenes (derived from 2 isoprene units) such as myrcene; sesquiterpenes (derived from 3 isoprene units) such as amorpha-4,11-diene; diterpenes (derived from four isoprene units) such as taxadiene; triterpenes (derived from 6 isoprene units) squalene; tetraterpenes (derived from 8 isoprenoids) β-carotene; and polyterpenes (derived from more than 8 isoprene units) such as polyisoprene. In some embodiments, the isoprenoid is not a carotenoid. In other embodiments, the isoprenoid is a C5-C20 isoprenoid.
  • C5 compounds may be derived from IPP or DMAPP. These compounds are also known as hemiterpenes because they are derived from a single isoprene unit (IPP or DMAPP).
  • Isoprene, whose structure is
  • Figure US20130316383A1-20131128-C00001
  • is found in many plants and is made from IPP by isoprene synthase.
  • C10 compounds may be derived from geranyl pyrophosphate (GPP), which is made by the condensation of IPP with DMAPP. An enzyme known to catalyze this step is, for example, geranyl pyrophosphate synthase. These C10 compounds are also known as monoterpenes because they are derived from two isoprene units. GPP can be further processed to a monoterpene.GPP is then subsequently converted to a variety of C10 compounds. Illustrative examples of C10 compounds include but are not limited to:
  • Carene, whose structure is
  • Figure US20130316383A1-20131128-C00002
  • is found in the resin of many trees, particularly pine trees. Carene is made from GPP from carene synthase.
  • Geraniol (also known as rhodnol), whose structure is
  • Figure US20130316383A1-20131128-C00003
  • is the main component of oil-of-rose and palmarosa oil. It also occurs in geranium, lemon, and citronella. Geraniol is made from GPP by geraniol synthase.
  • Linalool, whose structure is
  • Figure US20130316383A1-20131128-C00004
  • is found in many flowers and spice plants such as coriander seeds. Linalool is made from GPP by linalool synthase.
  • Limonene, whose structure is
  • Figure US20130316383A1-20131128-C00005
  • is found in the rind of citrus fruits and peppermint. Limonene is made from GPP by limonene synthase.
  • Myrcene, whose structure is
  • Figure US20130316383A1-20131128-C00006
  • is found in the essential oil in many plants including bay, verbena, and myrcia from which it gets its name. Myrcene is made from GPP by myrcene synthase.
  • α- and β-Ocimene, whose structures are
  • Figure US20130316383A1-20131128-C00007
  • respectively, are found in a variety of plants and fruits including Ocimum basilicum and is made from GPP by ocimene synthase.
  • α-Pinene, whose structure is
  • Figure US20130316383A1-20131128-C00008
  • is found in pine trees and eucalyptus. α-Pinene is made from GPP by α-pinene synthase. β-Pinene
  • β-Pinene, whose structure is
  • Figure US20130316383A1-20131128-C00009
  • is found in pine trees, rosemary, parsley, dill, basil, and rose. β-Pinene is made from GPP by β-pinene synthase.
  • Sabinene, whose structure is
  • Figure US20130316383A1-20131128-C00010
  • is found in black pepper, carrot seed, sage, and tea trees. Sabinene is made from GPP by sabinene synthase.
  • γ-Terpinene, whose structure is
  • Figure US20130316383A1-20131128-C00011
  • is a constituent of the essential oil from citrus fruits. Biochemically, γ-terpinene is made from GPP by a γ-terpinenesynthase.
  • Terpinolene, whose structure is
  • Figure US20130316383A1-20131128-C00012
  • is found in black currant, cypress, guava, lychee, papaya, pine, and tea. Terpinolene is made from GPP by terpinolene synthase.
  • C15 compounds may be derived from farnesyl pyrophosphate (FPP) which is made by the condensation of two molecules of IPP with one molecule of DMAPP. An enzyme known to catalyze this step is, for example, farnesyl pyrophosphate synthase. These C15 compounds are also known as sesquiterpenes because they are derived from three isoprene units. Illustrative examples of C15 compounds include but are not limited to:
  • Amorphadiene, whose structure is
  • Figure US20130316383A1-20131128-C00013
  • is a precursor to artemisinin which is made by Artemisia anna. Amorphadiene is made from FPP by amorphadiene synthase.
  • α-Farnesene, whose structure is
  • Figure US20130316383A1-20131128-C00014
  • is found in various biological sources including but not limited to the Dufour's gland in ants and in the coating of apple and pear peels. α-Farnesene is made from FPP by α-farnesene synthase.
  • β-Farnesene, whose structure is
  • Figure US20130316383A1-20131128-C00015
  • is found in various biological sources including but not limited to aphids and essential oils such as from peppermint. In some plants such as wild potato, β-farnesene is synthesized as a natural insect repellent. β-Farnesene is made from FPP by β-farnesene synthase.
  • Farnesol, whose structure is
  • Figure US20130316383A1-20131128-C00016
  • is found in various biological sources including insects and essential oils such as from cintronella, neroli, cyclamen, lemon grass, tuberose, and rose. Farnesol is made from FPP by a hydroxylase such as farnesol synthase.
  • Nerolidol, whose structure is
  • Figure US20130316383A1-20131128-C00017
  • is also known as peruviol, and is found in various biological sources including as essential oils such as from neroli, ginger, jasmine, lavender, tea tree, and lemon grass. Nerolidol is made from FPP by a hydroxylase such as nerolidol synthase.
  • Patchoulol, whose structure is
  • Figure US20130316383A1-20131128-C00018
  • is also known as patchouli alcohol and is a constituent of the essential oil of Pogostemon patchouli. Patchouliol is made from FPP by patchouliol synthase.
  • Valencene, whose structure is
  • Figure US20130316383A1-20131128-C00019
  • is one of the main chemical components of the smell and flavour of oranges and is found in orange peels. Valencene is made from FPP by nootkatone synthase.
  • C20 compounds may be derived from geranylgeraniol pyrophosphate (GGPP) which is made by the condensation of three molecules of IPP with one molecule of DMAPP. An enzyme known to catalyze this step is, for example, geranylgeranyl pyrophosphate synthase. These C20 compounds are also known as diterpenes because they are derived from four isoprene units. GGPP can be further processed to a diterpene, or can be further processed to produce a carotenoid. Alternatively, GGPP can also be made by adding IPP to FPP. GGPP is then subsequently converted to a variety of C20 isoprenoids. Illustrative examples of C20 compounds include but are not limited to:
  • Geranylgeraniol, whose structure is
  • Figure US20130316383A1-20131128-C00020
  • is a constituent of wood oil from Cedrela toona and of linseed oil. Geranylgeraniol can be made by e.g., adding to the expression constructs a phosphatase gene after the gene for a GGPP synthase.
  • Abietadiene encompasses the following isomers:
  • Figure US20130316383A1-20131128-C00021
  • and is found in trees such as Abies grandis. Abietadiene is made by abietadiene synthase. Illustrative examples of C20+ compounds include sesterterpenes (C25 compound made from five isoprene units), triterpenes (C30 compounds made from six isoprene units), and tetraterpenes (C40 compound made from eight isoprene units).
  • In some embodiments, the fermentation methods of the invention may be used in the production of a combustible isoprenoid. The isoprenoid compounds described herein may, for example, be used as combustible materials or fuels.
  • Engineering Pathways
  • In some embodiments of the invention, the fermentation methods of the invention comprise adjusting a parameter of the initial fermentation condition by engineering MEV pathways to enhance production of isoprenoids in a host cell. The pathway is typically engineered via recombinant DNA technology by expressing heterologous sequences encoding enzymes in the pathway. The activity of a MEV pathway enzyme in a host can be altered in a number of ways, including, but not limited to, expressing a modified form of the enzyme that exhibits increased solubility in the host cell, expressing an altered form of the enzyme that lacks a domain through which the activity of the enzyme is inhibited, expressing a modified form of the enzyme that has a higher Kcat or a lower Km for the substrate, or expressing an altered form of the enzyme that is not affected by feed-back or feed-forward regulation by another molecule in the pathway. Such variant enzymes can also be isolated through random mutagenesis of a broader specificity enzyme, as described below, and a nucleotide sequence encoding such variant enzyme can be expressed from an expression vector or from a recombinant gene integrated into the genome of a host microorganism.
  • The yield of an isoprenoid via one or more metabolic pathways disclosed herein can be augmented by inhibiting reactions that divert intermediates from productive steps towards formation of the isoprenoid product. Inhibition of the unproductive reactions can be achieved by reducing the expression and/or activity of enzymes involved in one or more unproductive reactions. Such reactions include side reactions of the TCA cycle that lead to fatty acid biosynthesis, alanine biosynthesis, the aspartate superpathway, gluconeogenesis, heme biosynthesis, and/or glutamate biosynthesis, at a level that affects the overall yield of an isoprenoid production. Additionally, the conversion of acetyl-CoA to acetate via the action of phosphotransacetylase is another example of unproductive side reaction. Therefore, where desired, “knocking out” or “knocking down” the pta gene that encodes phosphotransacetylase may also be carried in order to increase the yield of isoprenoid production. Depending on the specific isoprenoid of interest, one skilled in the art may choose to target additional unproductive steps. For example, where carotenoid is the isoprenoid of choice, one may opt to “knock out” or “knock down” one or more genes selected from the group consisting of gdhA, aceE, fdhF, yjiD, hnr or yjfP, ackA, appY, aspC, clp, clpP, clpXP, crcB, csdA, cyaA, evgS, fdhA, fdhD, feoB, fumA, glnE, glxR, gntK, hycI, lipB, lysU, modA, moeA, nadA, nuoC, nuoK, pflB, pitA, pst, pstC, pta, p-yjiD, sohA, stpA, yagR, yaiD, ybaS, ycfZ, ydeN, yebB, yedN, yfcC, ygiP, yibD, yjfP, yjhH, or yliE genes, or any other genes alone or in combination, the inhibition of which would result in a higher yield of carotenoid as described in U.S. Patent Application 20060121558, which is incorporated herein by reference.
  • A variety of methods are available for knocking out or knocking down a gene of interest. For example, a reduced gene expression may be accomplished by deletion, mutation, and/or gene rearrangement. It can also be carried out with the use of antisense RNA, siRNA, miRNA, ribozymes, triple stranded DNA, and transcription and/or translation inhibitors. In addition, transposons can be employed to disrupt gene expression, for example, by inserting it between the promoter and the coding region, or between two adjacent genes to inactivate one or both genes.
  • Although the invention has been described in conjunction with specific embodiments thereof, the foregoing description is intended to illustrate and not limit the scope of the invention. Other aspects, advantages, and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.
  • EXAMPLES
  • The practice of the present invention can employ, unless otherwise indicated, conventional techniques of the biosynthetic industry and the like, which are within the skill of the art. To the extent such techniques are not described fully herein, one can find ample reference to them in the scientific literature.
  • The following examples are intended for illustrative purposes only and do not limit in any way the scope of the present invention. Variations and modifications to the following exemplary protocols and procedures are contemplated so long as they support quantitation of a cofactor and a metabolic pathway metabolite, or they support quantitation of a plurality of types of metabolites of a given pathway.
  • Example 1
  • LC/MS/MS was used to evaluate a set of standards representing mevalonate pathway metabolites and co-factors. The objective was to verify that both the metabolites and co-factors can be detected using the desired LC/MS/MS procedure.
  • Study Design.
  • Standards of the mevalonate pathway metabolite and co-factors were prepared and analyzed using LC/MS/MS and used to determine expected retention times. Metabolites were analyzed using P and N modes as mentioned below.
  • Buffer Preparation.
  • Ammonium Acetate Buffer −38.5 g ammonium acetate was added to 500 mL of 1 M Ammonium acetate in LC/MS grade water. The mixture was transferred to a 500 mL graduated cylinder. Water was added to make up 500 mL and the buffer was stored at 4° C. for future use.
  • 1 M Ammonium Hydroxide Buffer—17.5 g was added to HPLC grade water to a volume of 500 mL and stored at 4° C. for future use.
  • LC Solvent—To a clean LC solvent bottle and fresh pipettes, 960 mL of LC/MS grade water, 20 mL of ammonium acetate solution, and 20 mL of ammonium hydroxide solution was added. After the additions, the solution was mixed well. 50 mL of solvent was removed and transferred to a 50 mL falcon tube and stored at 4° C. for preparation of the extraction buffer. 50 mL acetonitrile was added to the LC solvent and the solution was mixed again.
  • Internal Standards—2 mg/mL stock solution for each internal standard was prepared in 50:50 MeOH:H2O buffer except for mevalonate. A stock solution of mevalonate was prepared in 50:50 MeOH: 20 mM ammonium acetate buffer (pH 9.4).
  • MeOH with Formic Acid—0.1 mL of 100% formic acid was added to 79.9 mL of LC/MS grade methanol and stored at 4° C.
  • Extraction Buffer—25 mL of LC solvent prepared above was added to 25 mL of LC/MS grade methanol. The solution was mixed well and stored at 4° C.
  • Run Conditions
  • HPLC Parameters are shown in Table 1.
  • TABLE 1
    HPLC Parameters
    Parameter Value LC gradient
    Mobile phase A 20 mM ammonium acetate Time Solvent B
    buffer with 5% acetonitrile (min) (%)
    Mobile phase B Acetonitrile 0 80
    Column Aminopropyl 25 20
    Column Temp 25° C. 30 20
    Flow Rate 0.2 mL/min 30.01 80
    Injection Volume  20 μL 37 End run
    Autosampler  4° C.
    temperature
    Gradient
    0 min = 80 % B
  • Mass Spectrometer Parameters are shown in Table 2.
  • TABLE 2
    Mass Spectrometer Parameters
    Parameter Value
    Spray voltage 3500 V (positive ionization mode)
    3000 V (negative ionization mode)
    Capillary temperature 350° C.
    Sheath gas 45 arbitrary units
    Aux gas
    15 arbitrary units
    Vaporizer temp 0
    Collision gas 1.5 Torr
    SRM scan width 1
    SRM scan time 0.1 sec
    Micro scans 2
  • Metabolite and Internal Standard SRMS
  • The SRM values for the metabolites and co-factors analyzed are shown in Table 3
  • TABLE 3
    Metabolite and Internal Standard SRMS
    Collision
    Parent ion Product ion energy
    mass mass (eV)
    Positive ionization mode
    AMP 348 136 21
    13C15N AMP (Internal standard for 363.1 146 21
    AMP)
    FAD 786 348 24
    AcetylCoA 810 303 28
    AcetoacetylCoA 852 345 34
    13C MalonylcoA (Internal standard for 857 305 30
    CoA's and FAD)
    3 HMGCoA 910 408 43
    Negative ionization mode
    Mevalonate 147 59 15
    Mevalonate additional SRM 147 41 30
    D7 mevalonate (Internal standard for 154 59 15
    mevalonate)
    Mevalonate P 227 79 20
    IPP/DMAPP 245 79 20
    Mevalonate PP 307 79 20
    GPP 313 79 18
    FPP 382 79 21
    ADP 426 134 24
    13C15N TTP (Internal standard for all 493 159 31
    the metabolites monitored in negative
    mode except mevalonate)
    ATP 506 408 21
    NAD 662 540 19
    NADH 664 408 31
    NADP 742 620 18
    NADPH 744 408 34
  • Results.
  • Each mevalonate metabolite and co-factor was detected as shown by the data in FIGS. 3A-3C using LC/MS/MS. LC/MS/MS using P and N mode analysis allows for simultaneous detection and identification of the mevalonate pathway metabolites and co-factors. Usage of an aminopropyl column allows for analyte separate with defined peak shapes.
  • Example 2
  • S. cerevisiae or E. coli was grown in either shake flasks or fermentors with or without isopropyl myristate overlay. Cell samples from were extracted and mevalonate pathway metabolites and co-factors were analyzed using LC/MS/MS. The objective is to verify that intracellular mevalonate pathway metabolites and co-factors can be detected and that those metabolites and co-factors can be quantified.
  • Study Design.
  • Cell samples were prepared using a basic extraction method that allows for quantification of coA co-factors and other mevalonate pathway metabolites and co-factors. Using the LC/MS/MS procedure and results described in Example 1, intracellular metabolites and cofactors were identified and quantified. Linearity and reproducibility of the measured relative concentration was also evaluated.
  • Summary of the Extraction Procedure.
  • Generally, the extraction procedure involves immediately quenching the harvested cells using −80° C. methanol. The mixture is then centrifuged and supernatant is removed. The pellets are then re-suspended with extraction solvent and glass beads. The re-suspended pellets and glass beads are vortexed and then sonicated to break the cells open. The supernatant is collected and subsequent extractions can be performed to maximize recovery of the desired metabolites and co-factors. In some procedures, samples were immediately quenched with −80° C. methanol. After methanol removal by centrifugation, analytes were extracted in 2 rounds with 20 mM ammonium acetate buffer, pH 9.4:methanol (50:50 v/v). Extracts were analyzed by HILIC-MS/MS. Chromatography was performed on a Luna NH2 column (150×2.1, 3μ, Phenomenex) with solvent A (20 mM ammonium acetate buffer, pH 9.4) and solvent B (acetonitrile) with a gradient of 80% o 0% B in 25 min. Mass spectrometer (TSQ quantum ultra, ThermoFisher) was operated in MRM mode in both positive and negative ESI mode to cover all the metabolites and co-factors.
  • Detailed Protocol.
  • Extraction tubes were prepared by adding 1.6 mL of HPLC grade methanol to pre-induction samples or 0.8 mL of HPLC grade methanol to post-induction samples and then stored overnight at −80° C. An extraction buffer was prepared with internal standards by adding approximately 50 μl of internal standard mixture was to approximately 950 μL of extraction buffer. Extraction tubes were removed from −80° C. and placed on dry ice.
  • 400 or 200 μl of sample (depending on whether it was a pre-induction sample or post-induction sample respectively) was added into extraction tubes. (The sample was poured directly into MeOH and not on the walls of the tube as it would freeze on walls, making it difficult to re-suspend the cells). The tube was inverted 6 times and then stored on dry ice. The sample was then centrifuged immediately (within 2 minutes) in a refrigerated ultracentrifuge at 9000 rcf for 2 minutes and then stored on dry ice. The supernatant was then removed and the pellet was stored on wet ice. The pellet was then re-suspended in 400 μl of extraction solvent (pH 9.4) 20-25 glass beads were added to the re-suspended pellet and vortexed for 2 minutes. The re-suspended pellet was stored on wet ice for 10 min, vortexed for 1 min and then further stored on wet ice for an additional 5 minutes.
  • After vortexing, the sample was sonicated for 3 minutes in cold water. After sonication, the sample was centrifuged in a refrigerated microcentrifuge at 9000 rcf for 3 minutes at 4° C. Supernatant was transferred to a labeled microcentrifuge tube. The pellet was re-suspended in 400 μl of extraction buffer (pH 9.4) by pipetting and vortexed for 2 minutes. The re-suspended pellet was stored on wet ice for 10 minutes, vortexed for 1 minute and then further stored on wet ice for an additional 5 minutes. After vortexing, the sample was sonicated for 3 minutes in cold water. After sonication, the sample was centrifuged in a refrigerated microcentrifuge at 9000 rcf for 3 minutes at 4° C. Supernatant was combined with the supernatant from the previous extraction.
  • The combined supernant was vortexed for 1 minute. Samples were immediately diluted for LC analysis in fresh 1.5 mL tubes. 3× dilution were performed for negative mode runs: 100 μl of extract was added to 200 μl of HPLC grade methanol. 5× dilution were performed for positive mode runs: 100 μl of extract was added to 400 μl of methanol with 0.125% formic acid. Diluted samples were stored on wet ice for 5 minutes. The samples were centrifuged at 18,000 rcf for 3 minutes at 4° C. 250 μl was transferred from each tube to a corresponding vial for LC analysis and stored on dry ice until analysis or frozen at frozen at −80° C.
  • If the cells were grown in the presence of a hydrophobic overlay (e.g. methyl oleate or isopropyl myristate), the an optional washing step can be added. This washing step could occur after the quenching reaction when the quenching mixture is centrifuged. A washing solvent such as chloroform can be added to the cell pellet. Alternatively, the washing step could occur prior to the basic supernatant is divided into aliquots for analysis. For example, an amount of cold chloroform can be added and then centrifuged. After centrifugation, the top most layer is removed and discarded. The supernatant can then be processed as previously described. This optional washing step allows for better reproducibility in samples where cells are grown in the presence of a hydrophobic overlay.
  • Storage of Final Extract.
  • If necessary, final extracts were stored at −80° C. for 6 days. The diluted (final methanol dilution) extracts were stored in eppendorf tubes (not the LC vials). On the day of analysis, the frozen diluted extracts were thawed on wet ice and centrifuged at 18,000 rcf for 4 minutes at 4° C. 250 μl of the sample was then transferred to LC vials.
  • Sample Analysis.
  • Samples are analyzed using LC/MS/MS as described in Example 1.
  • Results.
  • Cells were extracted using the protocol described above and then analyzed using LC/MS/MS as described in Example 1. Illustrated results are shown in FIGS. 3A-3C. Each of the mevalonate pathway metabolites and co-factors showed a linear relationship between peak area and concentration of the analyte in the sample and the calculated R2 values are close to 1 (ranged from 0.894 to 0.999). As shown by Tables 4 and 5, the inventive methods showed good intra-day and inter-day reproducibility. Overall extraction reproducibility was determined to be 5-10%.
  • TABLE 4
    Intra-day reproducibility (3 injections in a day)
    L_RSD_Intra-day M_RSD_Intra-day H_RSD_Intra-day
    (0.3 ug/ml) (1.5 ug/ml) (10 ug /ml)
    Acetoacetyl  3.60 4.44 3.39
    CoA
    GPP 20.65 3.16 1.07
    TTP 14.00 2.43 7.79
  • TABLE 5
    inter-day reproducibility (3 days)
    L_RSD_Inter-day M_RSD_Inter-day H_RSD_Inter-day
    Acetoacetyl 19.83 9.64  4.79
    CoA
    GPP 16.78 8.02 11.16
    TTP 25.72 9.16  9.29
  • Example 3
  • The extraction method was performed at multiple conditions to achieve high stability and recovery of MEV pathway metabolites and co-factors. Efforts were made to ensure stability and recovery of CoA containing metabolites, non-coA containing metabolites, and co-factors.
  • Study Design.
  • The following parameters were investigated for highest stability and recovery of MEV pathway metabolites and co-factors: extraction solvent pH, ratio of extraction solvent to broth, number of extractions, acidification of the extracted metabolites.
  • Results.
  • The effects of extraction solvent pH on recovery of metabolites and co-factors are shown in FIGS. 4A-4B. Higher recovery of several co-factors and metabolites, including NADH and FPP, were observed when a basic extraction buffer was used. A higher recovery level of both NADP and NADPH was observed when the broth to extraction solvent ratio was 1:2 (versus a 1:1 and 1:4). Higher recovery of the MEV pathway metabolites and co-factors was observed after two extractions using 50% methanol and 50% water with 20 mM ammonium acetate (pH 9.4) in comparison to a single extraction or three extractions.
  • The stability of Acetyl-CoA, HMG-CoA, Mevalonate, FPP, ADP, ATP, NADH, FAD, and AcAc-CoA is shown over time in FIG. 5. The amount of AcAc-CoA recovered after 20 hours is significantly lower than after 0 hours. The effect of formic acid addition to the extract for acidification is shown in FIG. 6. AcAc-CoA is stable in the acidified extract for at least 24 hours.
  • Example 4
  • Quenching of cells was evaluated to ensure proper final temperature after addition of −80° C. methanol to broth and to evaluate how much metabolite was lost due to the quenching process.
  • Study Design.
  • Temperature of a mixture of 30° C. water and −80° C. methanol was measured after mixing ratios of water to methanol from 1:1 to 1:4. An optimal ratio for water to methanol was evaluated for recovery of MEV pathway metabolites and co-factors using LC/MS/MS.
  • Results.
  • The various rations of water and methanol results in different temperatures from −5° C. to −30° C. A water to methanol ratio of 1:4 results in a temperature of approximately −30° C. and use of this ratio results in no significant loss of analytes during the quenching step.
  • Quenching of cells was evaluated to ensure proper final temperature after addition of −80° C. methanol to broth and to evaluate how much metabolite was lost due to the quenching process.
  • Study Design.
  • Temperature of a mixture of 30° C. water and −80° C. methanol was measured after mixing ratios of water to methanol from 1:1 to 1:4. An optimal ratio for water to methanol was evaluated for recovery of MEV pathway metabolites and co-factors using LC/MS/MS.
  • Results.
  • The various ratios of water and methanol results in different temperatures from −5° C. to −30° C. A water to methanol ratio of 1:4 (broth to quenching solvent) results in a temperature of approximately −30° C. and use of this ratio results in no significant loss of analytes during the quenching step. FIG. 7 shows the temperature of the sample for the various processing step.
  • Example 5
  • Various different quenching solvents were tested to revisit whether a 100% methanol was the best quenching solvent. Based on fluidity and ease of handling at −80° C., methanol and glycerol were chosen. Thirteen different quenching solvent mixtures were tested:
      • 5% glycerol; 30% water; 65% methanol
      • 10% glycerol; 30% water; 60% methanol
      • 10% glycerol; 10% water; 80% methanol
      • 20% glycerol; 20% water; 60% methanol
      • 20% (v/v) glycerol/methanol
      • 40% (v/v) glycerol/methanol
      • 20% (v/v) water/methanol
      • 30% (v/v) water/methanol
      • 35% (v/v) water/methanol
      • 40% (v/v) water/methanol
      • 50% (v/v) water/methanol
      • 40% (v/v) HEPES/methanol
      • 100% methanol
  • Study Design.
  • Cell sampling was accomplished by quenching requisite amounts of yeast culture in −80° C. solvent. For optical densities below 1.0 OD, 3 mL of broth was quenched in 12 mL solvent. For optical densities greater than 1.0 OD, 0.4 mL of broth was quenched in 1.6 mL solvent. Samples were immediately centrifuged at 4500 rpm for 3 minutes at −7° C. for low OD, while high OD samples were centrifuged at 9000 rcf for 3 minutes at −10° C. After centrifugation, supernatant was removed analyzed for potential intracellular metabolite leakage. Sample pellets were kept on wet ice, where 200 μl internal standard spiked extraction buffer (50 μL internal standard per mL 20 mM ammonium acetate buffer) and glass beads were added and vortexed. Samples were sonicated in a wet ice bath for 3 minutes and placed on wet ice for 10 minutes, vortexed and subject to an additional 5 minutes on ice. Samples were then centrifuged at 9,000 rcf for 3 minutes, at 4° C. Extract was removed and the extraction procedure was repeated. Extract was pooled, diluted twice with methanol and analyzed by LCMSMS.
  • Results.
  • As it can be seen from FIGS. 8A-8D, the best quenching solvent was determined to be 5% glycerol; 30% water; 65% methanol. Prior art quenching solvents have described the use of buffered or un-buffered 60% methanol (at or below −40° C.) which is a standard way of rapidly arresting metabolic activity. However, because of concerns of the likelihood of leakages of intra-cellular metabolites during the quenching reaction, quenching solvents that minimize such leakage have been explored. For examply, one type of such solvents are glycerol-containing ones where glycerol is present in high concentrations (greater than 30%). A commonly used example is 40% glycerol in Hepes buffer. However, the use of this solvent requires that quenching occur at −23° C. as the solvent mixture freezes below this temperature. Moreover, although it is possible to decrease the freezing point by the addition of methanol, the high glycerol concentration (e.g. greater than 30%) makes the analysis of extra-cellular metabolites difficult, if not impossible due to chemical derivatization issues as well as signal interference by glycerol in gas chromatography analysis.
  • Methanol water combinations suffer from many of the same issues as glycerol saline combinations. Low freezing point and metabolite leakage prevent this from being a quenching solvent if one is interested in detecting a wide range of metabolites.
  • 100% methanol is an excellent quenching solvent under most circumstances, particularly in high cell density situations such as high density fermentations (optical density600 30-200). However, for low density fermentors and shake flask models (optical density600 0.3-15), the metabolite signals are highly variable and there is significant ion suppression. In these low cell density situations, the addition of glycerol appears to improve signal detection by reducing ion suppression effect. In other words, the signal intensity is significantly removed by less salt precipitation. As it can be seen by FIG. 9, 5% glycerol is sufficient to avoid salt precipitation and significantly improve signal quality. However, up to 20% glycerol can be used without introducing lengthy centrifugation step without significant adhering to sample vials.
  • Metabolites.
  • The metabolites analyzed by this method using 5% glycerol; 30% water; 65% methanol as the quenching solvent include aminoacids, nucleoside bases, nucleosides, nucleoside monophosphates, nucleoside di/triphosphates, CoAs, carboxylic acids and redox-electron carriers and precursors. The amino acids include: alanine, arginine, asparagines, glutamate, glutamine, histidine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. The nucleoside bases include: adenine, cytosine, guanine, and uracil. The nucleosides include: adenosine, cytidine and guanosine. The nucleoside monophosphates include: AMP, CMP, cyclic-AMP, dGMP, and GMP. The nucleoside di/triphosphates include: ADP, ATP, CDP, CTP, GTP, TTP, and UDP. The CoAs include: HMG-CoA, acetoacetyl CoA, acetyl-CoA, CoA, dephospho-CoA, and malonyl CoA. The carboxylic acids include: citrate, fumarate, malate, and succinate. The redox-electron-carriers and precursors include: FAD, FMN, NAD+, NADPH, oxidized glutathione, and reduced glutathione.
  • Example 6
  • The sensitivity of the method of Example 1 could be improved by moving the analysis of certain metabolites from negative to positive mode. Metabolites NAD, NADH, NADP, NADPH, ATP and ADP were moved from negative to positive mode ionization for mass spectrometry analysis. Table 6 details the internal standards, metabolites and the mode of analysis.
  • TABLE 6
    Metabolite and Method of Analyses
    Metabolite Internal Standard Mode of Analysis
    AMP, FAD, GSH, GSSG 13C10 15N5 AMP positive
    AcCoA, Acetoacetyl CoA, 3- 13C3 malonyl CoA positive
    HMGCoA
    NAD, NADH, NADP NHD positive
    NADPH NHDPH Positive
    ATP, ADP 13C10 15N5 ATP positive
    MVP Hydroxyl-FP negative
    Mevalonate D7 mevalonate Negative
    MVPP, IPP, DMAPP, GPP, FPP Thio-FPP negative
  • FIGS. 10A-10B show the improved sensitivity of ATP, NADH, and NADPH when the method of analysis is switched from negative to positive mode.

Claims (36)

1-17. (canceled)
18. An extract from a cell comprising one or more cofactors and one or more mevalonate pathway metabolites, wherein the extract exhibits a pH value of 8 or greater and comprises an alcohol, and wherein the cofactor and the metabolite are stable in said extract for at least about 8 hours.
19. The extract of claim 18 wherein the one or more cofactors and one or more mevalonate pathway metabolites are stable in said extract for at least about 12 hours.
20. The extract of claim 18 wherein the alcohol is methanol.
21. The extract of claim 18 that is quenched at a temperature below −23° C. with a quenching solvent that is a liquid at −80° C.
22-29. (canceled)
30. The extract of claim 18, wherein the one or more cofactors are selected from the group consisting of NAD+, NADP+, NADH, NADPH, AMP, ADP and ATP.
31. The extract of claim 18, wherein the one or mevalonate pathway metabolites are selected from the group consisting of acetyl CoA, acetoacetyl-CoA, 3-hydroxy-3-methylglutaryl-CoA, farnesyl pyrophosphate, geranyl pyrophosphate, isopentenyl pyrophosphate, dimethylallyl pyrophosphate, mevalonate, mevalonate phosphate, and mevalonate pyrophosphate.
32. The extract of claim 18, wherein the cell is prokaryotic.
33. The extract of claim 18, wherein the cell is eukaryotic.
34. The extract of claim 18, wherein the cell is a bacterial cell.
35. The extract of claim 18, wherein the cell is a yeast cell.
36. The extract of claim 34, wherein the yeast is Saccharomyces cerevisiae.
37. The extract of claim 18, wherein the alcohol is ethanol.
38. The extract of claim 18, wherein the extract exhibits a pH value of 9 or greater.
39. The extract of claim 18, wherein the extract further comprises a basic buffer.
40. The extract of claim 39, wherein the basic buffer is an ammonium salt.
41. The extract of claim 40, wherein the ammonium salt is ammonium chloride or ammonium acetate.
42. The extract of claim 39, wherein the ratio of alcohol to basic buffer in the extract is 1:1.
43. The extract of claim 39, wherein the ratio of alcohol to basic buffer in the extract is greater than 2.
44. The extract of claim 18, wherein the cell comprises an enzyme that catalyzes the formation of acetoacetyl-CoA from two molecules of acetyl-coenzyme A.
45. The extract of claim 44, wherein the enzyme is acetyl-CoA thiolase.
46. The extract of claim 18, wherein the cell comprises an enzyme that catalyzes the formation of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) from acetyl-coenzyme A and acetoacetyl-CoA.
47. The extract of claim 46, wherein the enzyme is HMG-CoA synthase.
48. The extract of claim 18, wherein the cell comprises an enzyme that catalyzes the formation of mevalonate from HMG-CoA.
49. The extract of claim 48, wherein the enzyme is HMG-CoA reductase.
50. The extract of claim 18, wherein the cell comprises an enzyme that catalyzes the formation of mevalonate 5-phosphate from mevalonate.
51. The extract of claim 50, wherein the enzyme is mevalonate kinase.
52. The extract of claim 18, wherein the cell comprises an enzyme that catalyzes the formation of mevalonate 5-pyrophosphate from mevalonate 5-phosphate.
53. The extract of claim 52, wherein the enzyme is phosphomevalonate kinase.
54. The extract of claim 18, wherein the cell comprises an enzyme that catalyzes the formation of isopentenyl pyrophosphate from mevalonate 5-pyrophosphate.
55. The extract of claim 54, wherein the enzyme is mevalonate pyrophosphate decarboxylase.
56. The extract of claim 18, wherein the cell comprises an enzyme that catalyzes the conversion of isopentenyl pyrophosphate to dimethylallyl pyrophosphate.
57. The extract of claim 56, wherein the enzyme is isopentenyl pyrophosphate isomerase.
58. The extract of claim 18, wherein the cell comprises an enzyme that catalyzes the sequential condensation reactions of dimethylallyl pyrophosphate with two units of 3-isopentenyl pyrophosphate to form farnesyl pyrophosphate.
59. The extract of claim 58, wherein the enzyme is farnesyl pyrophosphate synthase.
US13/870,911 2008-01-31 2013-04-25 Methods of monitoring metabolic pathways Abandoned US20130316383A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/870,911 US20130316383A1 (en) 2008-01-31 2013-04-25 Methods of monitoring metabolic pathways

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6325808P 2008-01-31 2008-01-31
US12/361,478 US8450080B2 (en) 2008-01-31 2009-01-28 Methods of monitoring metabolic pathways
US13/870,911 US20130316383A1 (en) 2008-01-31 2013-04-25 Methods of monitoring metabolic pathways

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/361,478 Division US8450080B2 (en) 2008-01-31 2009-01-28 Methods of monitoring metabolic pathways

Publications (1)

Publication Number Publication Date
US20130316383A1 true US20130316383A1 (en) 2013-11-28

Family

ID=40913205

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/361,478 Active 2031-07-22 US8450080B2 (en) 2008-01-31 2009-01-28 Methods of monitoring metabolic pathways
US13/870,911 Abandoned US20130316383A1 (en) 2008-01-31 2013-04-25 Methods of monitoring metabolic pathways

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/361,478 Active 2031-07-22 US8450080B2 (en) 2008-01-31 2009-01-28 Methods of monitoring metabolic pathways

Country Status (4)

Country Link
US (2) US8450080B2 (en)
EP (1) EP2247746A4 (en)
BR (1) BRPI0906620A8 (en)
WO (1) WO2009097339A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119340A1 (en) * 2012-02-08 2013-08-15 Glycos Biotechnologies, Inc. Microorganism and process for isoprene production
CN112466671B (en) * 2020-12-02 2022-03-11 广东省农业科学院作物研究所 Nitrogen-self-doped tobacco stem-based activated carbon electrode material and preparation method and application thereof
WO2023031793A1 (en) * 2021-08-31 2023-03-09 King Abdullah University Of Science And Technology Biocompatible underlays for living extraction of hydrocarbons from engineered microbes
CN114280189B (en) * 2021-12-24 2022-09-09 大连理工大学 Method for quickly and quantitatively analyzing fermentation metabolites of microbial cell factory

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946952A (en) * 1987-04-24 1990-08-07 Hoffmann-La Roche Inc. Process for isolating nucleic acids
US5510267A (en) * 1989-05-15 1996-04-23 Abbott Laboratories Flow cytometry lytic agent and method enabling 5-part leukocyte differential count

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002078689A1 (en) 2001-03-30 2002-10-10 The Nisshin Oillio, Ltd. Bone metabolism improving agents
US7172886B2 (en) 2001-12-06 2007-02-06 The Regents Of The University Of California Biosynthesis of isopentenyl pyrophosphate
US7192751B2 (en) 2001-12-06 2007-03-20 The Regents Of The University Of California Biosynthesis of amorpha-4,11-diene
JP2007507234A (en) 2003-09-29 2007-03-29 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア Methods for identifying biosynthetic pathway gene products
US7741070B2 (en) 2003-12-24 2010-06-22 Massachusetts Institute Of Technology Gene targets for enhanced carotenoid production
AU2005327292B2 (en) * 2004-05-21 2010-11-04 The Regents Of The University Of California Method for enhancing production of isoprenoid compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946952A (en) * 1987-04-24 1990-08-07 Hoffmann-La Roche Inc. Process for isolating nucleic acids
US5510267A (en) * 1989-05-15 1996-04-23 Abbott Laboratories Flow cytometry lytic agent and method enabling 5-part leukocyte differential count

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Konstantinopoulos et al. (Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nature Reviews Drug Discovery (2007) Figure 1) *
Qiagen (Genomic DNA Purification (2002) pages 10-13) *
Wallace et al (Mitochondria and Cancer. Nature Reviews: Cancer (2012) pages 685-698) *
Wikipedia ("Ethanol Metabolism") *

Also Published As

Publication number Publication date
EP2247746A1 (en) 2010-11-10
WO2009097339A1 (en) 2009-08-06
BRPI0906620A2 (en) 2015-07-14
US20090203019A1 (en) 2009-08-13
BRPI0906620A8 (en) 2016-01-19
EP2247746A4 (en) 2012-08-01
US8450080B2 (en) 2013-05-28
WO2009097339A9 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
US10106822B2 (en) Production of isoprenoids
Luo et al. Enhancing isoprenoid synthesis in Yarrowia lipolytica by expressing the isopentenol utilization pathway and modulating intracellular hydrophobicity
EP2217711B1 (en) Production of isoprenoids
Engel et al. Acetohydroxyacid synthase: a new enzyme for chiral synthesis of R‐phenylacetylcarbinol
JP7105783B2 (en) Production of citronellal and citronellol in recombinant hosts
US20130316383A1 (en) Methods of monitoring metabolic pathways
EP2238257A2 (en) Process for production and quantitation of high yield of biobutanol
Rossoni et al. The putative mevalonate diphosphate decarboxylase from Picrophilus torridus is in reality a mevalonate-3-kinase with high potential for bioproduction of isobutene
Dipeolu et al. Effects of water-miscible ionic liquids on cell growth and nitro reduction using Clostridium sporogenes
Varela et al. Systems-based approaches enable identification of gene targets which improve the flavour profile of low-ethanol wine yeast strains
CN114207139A (en) Method for uncoupling yield and productivity of non-catabolic compounds produced by a host cell
WO2008076758A2 (en) Nerolidol, terpene, and terpene derivative synthesis
Nie et al. Biological insights into non-model microbial hosts through stable-isotope metabolic flux analysis
Fakankun et al. Proteomic analyses of the oleaginous and carotenogenic yeast Rhodotorula diobovata across growth phases under nitrogen-and oxygen-limited conditions
Yang et al. Metabolomics of astaxanthin biosynthesis and corresponding regulation strategies in Phaffia rhodozyma
EP3574105B1 (en) Co-production of a sesquiterpene and a carotenoid
Seker et al. Analysis of acyl CoA ester intermediates of the mevalonate pathway in Saccharomyces cerevisiae
CN114280189B (en) Method for quickly and quantitatively analyzing fermentation metabolites of microbial cell factory
Gläser et al. A common approach for absolute quantification of short chain CoA thioesters in industrially relevant gram-positive and gram-negative prokaryotic and eukaryotic microbes
NL2031273B1 (en) Bioproduction of bakuchiol
Magdenoska et al. Quantifying intracellular metabolites in yeast using a matrix with minimal interference from naturally occurring analytes
WO2023044937A1 (en) Genetically modified yeast of the genus yarrowia capable of producing vitamin a
AU2012202630B2 (en) Production of isoprenoids
Buzzini et al. Production of flavoured volatile organic compounds (VOCs) by Candida oleophila GK10: Optimisation using factorial design and response surface analysis
Hu et al. Metabolomics analysis of carotenoid production from Proteiniphilum acetatigenes PSB-W based on LC-MS

Legal Events

Date Code Title Description
AS Assignment

Owner name: MAXWELL (MAURITIUS) PTE LTD, SINGAPORE

Free format text: SECURITY AGREEMENT;ASSIGNOR:AMYRIS, INC.;REEL/FRAME:031478/0933

Effective date: 20131016

AS Assignment

Owner name: TOTAL ENERGIES NOUVELLES ACTIVITES USA, FRANCE

Free format text: SECURITY AGREEMENT;ASSIGNOR:AMYRIS, INC.;REEL/FRAME:031607/0314

Effective date: 20131016

AS Assignment

Owner name: AMYRIS, INC., CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:TOTAL ENERGIES NOUVELLES ACTIVITES USA, SAS (F/K/A TOTAL GAS & POWER USA, SAS);REEL/FRAME:032554/0001

Effective date: 20131203

AS Assignment

Owner name: AMYRIS, INC., CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MAXWELL (MAURITIUS) PTE LTD;REEL/FRAME:032578/0357

Effective date: 20131202

AS Assignment

Owner name: AMYRIS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AMYRIS BIOTECHNOLOGIES, INC.;REEL/FRAME:032849/0554

Effective date: 20100618

Owner name: AMYRIS BIOTECHNOLOGIES, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAJAD, SUNIL;LEAVELL, MICHAEL;REEL/FRAME:032848/0261

Effective date: 20090226

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: HERCULES TECHNOLOGY GROWTH CAPITAL, INC., CALIFORNIA

Free format text: SECURITY INTEREST;ASSIGNOR:AMYRIS, INC.;REEL/FRAME:038878/0381

Effective date: 20140329

Owner name: HERCULES TECHNOLOGY GROWTH CAPITAL, INC., CALIFORN

Free format text: SECURITY INTEREST;ASSIGNOR:AMYRIS, INC.;REEL/FRAME:038878/0381

Effective date: 20140329

AS Assignment

Owner name: STEGODON CORPORATION, MASSACHUSETTS

Free format text: SECURITY INTEREST;ASSIGNOR:HERCULES CAPITAL INC.;REEL/FRAME:039048/0251

Effective date: 20160615

AS Assignment

Owner name: AMYRIS, INC., CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:STEGODON CORPORATION;REEL/FRAME:050206/0606

Effective date: 20180629